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Abstract 
Fungi represent a diverse resource in the discovery of new secondary metabolites 
which have been successfully developed as drugs such as antibiotics, immunosuppressant 
and stains. However, there are still problems which could potentially restrain the 
development of fungal natural products drug discovery, such as the confusing taxonomy 
annotation in NCBI, the deficiency of high capacity screening platforms as well as 
application of well recognized screening models, and the limited therapeutic diversity. 
With the aim to discover new fungal secondary metabolites, one efficient approach is to 
access new biodiversity. In this dissertation, we report the application of this approach in 
three chapters. 
The kingdom Fungi is comprised of highly diverse taxa with an estimated of 2.2 - 
3.8 million species on earth, of which only 5% have been described. Morphological 
characterization and DNA barcoding have served as the major strategies in fungal 
identification, with the latter considered as the universal tool. One of the growing 
problems of using DNA barcode data to identify fungi centers on the increasing number 
of GenBank sequence accessions that fall into the category of “insufficiently identified”. 
This has important implications for natural product chemical discovery since it is 
presumed that chemically unexplored fungal species are more likely to serve as sources 
of new natural products as opposed to well-known organisms whose secondary 
metabolomes have been thoroughly investigated. In this chapter, we propose a schema for 
using ITS barcode data to mine GenBank and identify high priority fungal isolates as 
potential sources of new natural products. In addition, we conducted a chemical analysis 
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of one high-priority fungal isolate demonstrating that most of its major metabolites were 
previously unreported natural products. 
The sexually transmitted parasite Trichomonas vaginalis infects at least 170 
million people worldwide and infections are treated with the lone compound 
metronidazole, a suspected human carcinogen. Reports of resistance to the drug are 
increasing. Thus, new drug leads are needed with which to treat this and other anaerobic 
parasites. An assay was developed in order to quantify the growth, viability, and 
morphology of the Trichomonas organism, using the Perkin Elmer Operetta imaging 
platform. A counter-screen for toxicity was also developed using the normal human 
cervical cell line Ect1/E6E7 and the Operetta. Screening of a library of 430 pure 
compounds yielded compounds with selectivity indices (SI) as high as 14. Further 
screening of our fungal crude extract library and bioassay-guided isolation revealed many 
promising leads for potent anti-Trichomonas compounds that remain safe to human cells. 
The tetramic acid derivatives rose to the forefront, such as beauversetin (SI = 40), 
equisetin (SI = 20), and pyrrolocin A (SI = 167). Manipulation of oxygen levels revealed 
that beauversetin retained activity. An additional test against Lactobacillus acidophilus, a 
beneficial natural flora organism found in the genital tract, was used as a counterscreen. 
Growth in an anaerobic atmosphere revealed that tetramic acid derivatives like pyrrolocin 
A behaved like metronidazole and did not disrupt the growth of L. acidophilus. 
Lastly, zebrafish has been utilized as a model organism for chemical screening to 
discover novel bioactive compounds. Phenotype-based zebrafish screening of a fungal 
crude extract library yielded an active fungal extract from a Penicillium sp. isolate. 
Bioassay-guided and chemistry-guided purification led to the identification of fourteen 
	   xvi	  
meroterpenoids including six new and seven known arisugacins and one known 
terrulactone. Their structures were determined using a combination of NMR and 
HRESIMS data, as well as the theoretical and experimental ECD spectra, and modified 
Mosher’s method. The purified compounds were tested in zebrafish embryos as well as in 
vitro for acetylcholinesterase inhibition activity. Compound 5.12 produced defects in 
myotome structure (metameric muscle which is critical for locomotion) in vivo and 
showed the most potent activity with an IC50 of 191 nM in vitro. This study demonstrates 
the utility of using zebrafish bioassay-guided sample purification as an effective strategy 
to rapidly identify bioactive small molecules with therapeutic applications.
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Chapter 1: Fungal Natural Products as a Unique Source for Drug 
Discovery 
1.1 The importance of natural products in drug discovery 
Nature has been a source of medicinal metabolites for thousands of years. The 
history of treatment of disease with natural products (secondary metabolites) can be dated 
as early as 2600 BC in Mesopotamia. Other civilizations such as Egyptian, Chinese, 
Indian and Greek also contributed substantially to the development of natural products 
for the treatment of a variety of diseases.1-2  
In addition to the long history of usage, the diverse sources of natural products 
make natural products even more important in drug discovery. Natural products have 
been isolated from plants, microorganisms, marine organisms, vertebrates and 
invertebrates.3-5 There is no doubt that plants and microorganisms are the major sources. 
Out of approximately 1 million natural products, 60% are plant derived, and most of the 
remaining 40% are from microbes.6 As early as 2600 BC, the use of plant derived 
substances as medicine had been documented, while 700 drugs (most were plant origin) 
were known to be used in Egypt as well as the traditional medicine in China, India and so 
on.1-2 Modern natural products and natural products chemistry began with the isolation of 
plant derived metabolite morphine in 1803.7 This discovery was followed by the isolation 
of other active metabolites from plants, such as emetine,8 strychnine,9 atropin,10 
reserpine,11 artemisinin12 and the most widely used breast cancer drug paclitaxel13 (Figure 
1.1). Microbial modern natural product was initiated by the discovery of penicillin from 
fungus Penicillium notatum in 1929.14 Following this discovery, more antibiotics were 
isolated from microorganisms, such as tetracycline in 1945,15 chloramphenicol in 1947,16 
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and vancomycin in 195317. These discoveries played an essential role in saving human 
life as well as promoting the development of microbial natural products chemistry. In 
addition to plants and microorganisms, significant contributions to natural products also 
came from animals and marine organisms. Two successful stories are metabolites 
teprotide and ω-conotoxin, the former was isolated from snake and used as lead 
compound for the development of antihypertension drug captopril, the latter was a marine 
derived metabolite and used to relieve severe and chronic pain.18-19 
 
 
Figure 1.1. Secondary metabolites isolated from plants. 
	  
What is more, the excellent chemical diversity and the “naturally active” features 
of natural products also inspired the discovery of new drugs and drug leads, which led to 
a complementary approach to synthetic chemistry.20 Diversity-oriented synthesis is a 
successful strategy for increasing skeletal diversity starting with an active natural 
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products. Additionally, total synthesis was also applied to natural products for assisting 
structure elucidation and identification of pharmacophores (e.g., halichondrin).2, 21  
Between the 1940s to the end of 2014, 49% of the 175 molecules approved 
anticancer drugs were either natural products or natural product derivatives.22 Among the 
74 antihypertensive drugs, approximately 65% were natural products.6 A recent review 
published in Journal of Natural Products summarized the percentage of natural products 
in approved new drugs over the period 1981 to 2014, it showed that 20~50% of new 
drugs were natural products or natural product based.22 These data support the position 
that nature has been and will continue to be a major source for drug discovery. 
	  
1.2 Fungal natural products in drug discovery 
The fungal kingdom is a well-known and valuable source of potential therapeutic 
compounds. Of the 23,000 microbial derived active metabolites, 42% were from fungi.6 
The discovery of penicillin was the beginning of fungal natural products,14 and since then 
there was a worldwide effort to discover antibiotics from fungi. The β-lactams were one 
of the successful discoveries, which includes penicillins, cephalosporins, monobactams 
and carbapenems.23 Among these antibiotics, mainly penicillins (e.g., amoxicillin, 
ampicillin), and cephalosporins (e.g., cefalotin, cefuroxime) (Figure 1.2), represented 
approximately 65% of the world antibiotic market.24 In addition to the outstanding 
discovery of antibiotics, fungal natural products gained fame for their use as immune-
suppressive (e.g.,cyclosporine A25), and antifungal agents (e.g., griseofulvin,26 
echinocandins 27) (Figure 1.2) as well as agricultural fungicides (e.g., strobilurins 28) . 
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Figure 1.2. Examples of drugs derived from fungi. 
	  
Although to date no fungal natural products have been used as anti-cancer drugs 
clinically, plenty of compounds with documented anticancer activities are being studied 
and have promise to be potential cancer treatments. For example, fusarisetin A, isolated 
from Fusarium sp., is a potent cancer migration inhibitor for different types of cancer,29-30 
and ophiobolin A is a potent inducer of glioblastoma cell death by induction of paraptosis 
(Figure 1.3).31 The indole alkaloidal fungal metabolite tryprostatin A isolated from 
Aspergillus fumigatus, is an inhibitor of mitogen activated protein kinase dependent 
microtubule assembly which leads promoter the cell progression at the mitotic phase,32 
and peribysin A is a cell-adhesion inhibitors (Figure 1.3)33. Fungal natural products have 
also been investigated for other medical purposes, such as the anti-malarial metabolites 
pycnidione34 and codinaeopsin,35 anti-tuberculosis compound trichoderin A36 (Figure 1.3). 
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Figure 1.3. Examples of secondary metabolites from fungi. 
	  
Besides these chemically and functionally diverse fungal natural products, the 
extent of fungal diversity is even more remarkable. The fungal kingdom is comprised an 
estimation of 2.2 to 3.8 million species on earth.37 However, only 5% have been 
identified so far (16% of them have been cultured) leaving a wide field of potential 
producers of novel metabolites producers. 6, 38-39 In addition, the application of synthetic 
biology to fungal natural products such as manipulating the natural products regulatory 
gene clusters, heterologous expression and engineering of the biosynthetic enzyme 
opened another field for novel metabolites production.40 The successfully stories include 
the production of novel metabolite aspyridones by expressing the pathway specific 
regulator to switch on a silent fungal pathway, the novel dipeptides by co-expressing of 
non-ribosomal synthetase and prenythransferase genes in Aspergillus.41-42 
As the need for new drugs and drug leads is still growing, natural products will 
continue to be a great source for drug discovery and chemical inspiration. Combining the 
chemical, functional diversity, the large number of fungal species, and the small fraction 
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of investigated species with the application of synthetic biology, fungal natural products 
will continue to play a substantial role in natural products drug discovery for many years 
to come. 
 
1.3 DNA barcoding as a tool for fungal identification 
Traditionally, fungal identification solely relied on the observation of 
morphological characteristics, such as the fruiting bodies and structures of spore.43 
However, the phenotypic approach is not applicable to some cases, including non-
sporulation and asexual fungi, high speciose fungi as well as uncultured fungi.44-47 
Therefore, alternatives to morphological analyses have been under consideration for a 
long time. Consequently, a more applicable tool, DNA sequence based approaches have 
emerged. 
DNA sequence based approach, also called DNA barcoding, compares query 
sequences against sequence database and identify fungi based on sequence similarity. The 
most commonly used barcodes are the large subunit, small subunit and internal 
transcribed spacer regions (ITS).48 The large subunit evolves slowest and can be used for 
higher level identification, such as family, order and class, while the ITS region 
possessing the highest variation and is the most useful barcode for genus and species 
identification.48-49 In addition, it was found that ITS region have a more than 90% PCR 
amplification fidelity, about 70% possibility of correct identification as well as the 
suitable barcode gap, which led it to be the official barcode for fungal identification.50-51 
However, the ITS region also has limitations and it does not work well for certain genera 
due to their narrow barcode gaps, such as Aspergillus and Penicillium.52-53 One solution 
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to this problem is the combination of the ITS region with other protein coding genes. The 
most commonly used genes are the largest subunit of RNA polymerase (RPB1) and 
second largest subunit of RNA polymerase (RPB2),54 β-tubulin (tub2/BenA)55 and the 
translation elongation factor 1-α (tef1)56. Among these genes, tub2/BenA was 
recommended as the secondary barcode for Penicillin sp.,57 while the tef1 gene was 
found to have promise to be the universal secondary barcode for fungal identification.58 
In addition to the aforementioned genes, the mini-chromosome maintenance protein 
(MCM7)59 and the partial calmodulin (CaM) genes have also showed promise as new 
barcode markers for fungal identification and was recommended as the secondary 
barcode for Aspergillus sp.60 
 
1.4 Fungi as a source of antiparasitic secondary metabolites 
Infectious disease caused by parasites is one major threat to human health and 
causes several million deaths every year.61 Although most parasites just cause severe 
discomfort instead of killing the hosts, there are still many deadly parasite infections such 
as malaria, trypanosomiasis and leishmaniosis.61 Very few vaccinations have been 
developed for parasite infections, and many infections still cannot be controlled by 
currently available treatments.62-63 However, most of these drugs have strong side effects 
(e.g., amphotericin B,64 metronidazole,65 benznidazole66) and in some cases, parasites 
have already gained resistance (e.g., chloroquine,67 sulfadoxine68) (Figure 1.4). Moreover, 
some patients give up on treatments due to the side effects and high cost, which aids in 
spreading the infections.63 The development of new drugs is needed urgently. But the fact 
is that investment in antiparasitic drug development is risky for pharmaceutical 
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companies because parasite infections usually occur in poor countries such as Latin 
America, Asia and Africa, where many drugs remain unaffordable.63 In addition, 
parasites share physiological similarity with hosts which makes it hard to develop drugs 
that are both effective and non-toxic to human.  
 
 
Figure 1.4. Examples of drug for parasites infection. 
	  
Fungal secondary metabolites have been an excellent source for treatments of a 
variety of disease, and some fungi have been used as traditional medicine to treat parasite 
infections (e.g., the Indian mushroom Autraeus hygrometricus is used to treat 
leishmaniosis). Studies aiming at finding new therapeutics from fungi have been done, 
and some anti-parasitic secondary metabolites including terpenes (e.g., aurisin A and K,69 
hypnophilin,70 astrakurkurone71), steroids,72 alkaloids (e.g., eurochevalierine,73 
hirsutellone F74), coumarins,75 proteins,76 and peptides (e.g., beauvericin,77 hirsutellic 
acid A78) have shown promising activities against various parasites (Figure 1.5). 
However, considering all the successfully stories for fungal natural products drug 
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discovery, the diversity of fungal sources as well as the secondary metabolites they 
produce, these are only the tip of the iceberg. Fungi will be a promising source for anti-
parasitic drug discovery, especially with the assistance of the high throughput screening 
strategy which allows more rapid and efficient identification process.79  
 
 
Figure 1.5. Antiparasitic secondary metabolites from fungi. 
	  
1.5 Meroterpenoids, selective acetylcholinesterase (AChE) inhibitors from fungi 
Meroterpenoids, with diverse structures and important bioactivities, are a class of 
hybrid natural products that are biosynthetically partially derived in part from terpenoids. 
They are most often isolated from fungi, and marine organisms, but there are also 
examples of meroterpenoids isolated from plants, such as tetrahydrocannabinol, isolated 
from cannabis, and bakuchiol which was isolated from Psoralea glandulosa L.80 
Territrems, arisugacins and terrulactones, mostly containing 𝔞-pyrone and triketide-
terpenoid, are meroterpenoids that were all isolated from fungi and all showed selective 
inhibition against AChE with varied potency. AChE is an enzyme which plays a key role 
in the hydrolysis of the neurotransmitter acetyl choline, and inhibition of AChE has been 
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reported as a strategy for the treatment of Alzheimer’s disease (AD),81-82 Parkinson’s 
disease,83 myasthenia gravis,84 glaucoma85. For examples, there are five medications 
currently used for AD treatment, four are AChE inhibitors. 
The first two compounds in this group (territrems, arisugacins and terrulactones) 
are territrem A and territrem B (Figure 1.6), isolated from Aspergillius terreus by Ling in 
1979, and were found to be the first two tremorgens without nitrogen.86 In 1984, the same 
group reported the isolation of a new analog territrem C (Figure 1.6), which was also a 
tremorgenic mycotoxin.87 Their structures were confirmed by 1D and 2D NMR.88 
Territrem B was incubated with rat liver microsomes which led to the production of four 
products MB1~MB4 , and MB4 was identical to territrem C.89-90 The inhibition of 
acetylcholinesterase (AChE) activity of territrems were discovered in 1992,91 followed by 
Omura’s work that showed they were highly selective AChE inhibitor compared with 
butyrylcholinesterase (BuChE), with the IC50 in nM range.92 Ling’s group reported the 
isolation of territrem A' and territrem B' (Figure 1.6), the structure of territrem B' was 
confirmed by single crystal x-ray diffractometry, the tremorgenic activity and inhibition 
effect on AChE of these two molecules were greatly reduced compared to territrem A and 
territrem B which indicated that the α, β-unsaturated carbonyl is important in the AChE 
inhibitive activity.93 In order to investigate the structure-activity relationship (SAR) in 
anti-AChE assay, Peng modified the structure of territrem B by epoxidation and 
saturation of the C-2 double bond, breaking the pyrone moiety, reduction of C-1 carbonyl 
and conversion of 4β-CH2OH into more hydrophobic and bulky group, to yield five 
derivatives.94 And Peng’s study indicated that both the enone and the pyrone moieties 
play important role in inhibitory activity of AChE.94 In 2014, another group reported the 
	   11	  
isolation of territrem D and territrem E (Figure 1.6), which also showed strong activity 
against AChE.95  
 
 
Figure 1.6. Structures of territrems. 
	  
Arisugacin (Figure 1.7) was isolated from Penicillium sp. FO-4259 together with 
structurally related compounds territrem B and C, and arisugacin showed even stronger 
selectivity inhibition of AChE than territrems.92 One year later, the same group isolated 
two more analogs, arisugacin A and B (Figure 1.7) from the same fungal species, and 
they both showed strong AChE inhibitive activity with arisugacin B slightly less 
potent.96-97 Fungal strain FO-4259 was treated with UV-light to yield a mutant strain, 
which lead to the isolation of arisugacin C~H,98 the absolute configuration of arisugacin 
F (Figure 1.7) was determined later by modified Mosher method.99 To determine the 
absolute configuration of arisugacin A and B, Sunazuka  did total synthesis of these two 
molecules, twelve intermediates were evaluated the inhibitory activities against AChE to 
better understand the SAR of arisugacins, they concluded the α, β-unsaturated carbonyl, 
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12a-hydroxy group and the E ring substituents were essential for the inhibition of AChE 
by arisugacins.100 Sun reported the isolation of arisugacin I and J from fungus Penicillium 
sp. SXH-65, with arisugacin I (Figure 1.7) being the first arisugacins with a linear 
sesquiterpenoid moiety.101 The cytotoxicity against HL-60, K562 and HeLa cells of 
arisugacins I and J were tested, both of them did not show any activity.101 Arisugacin K, 
an epimer of arisugacin E, was isolated by Li from an endophytic fungus Penicillium 
echinulatum, and showed inhibitory activity against Escherichia coli.102 These 
compounds have not been tested for AChE inhibition. 
 
 
Figure 1.7. Structures of arisugacins. 
	  
Terreulactones A~D (Figure 1.8), structurally related compounds to territrems and 
arisugacins, were isolated from Aspergillus terreus.103 They showed potent inhibitory 
activities against AChE with IC50 values in range of 0.06-0.42 µM.104 Seven-membered 
lactone type meroterpenoid, isoterreulactone A105 and 11a-dehydroxyisoterreulactone A95 
were isolated by Yoo and Nong. The inhibition against AChE of isoterreulactone A 
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(Figure 1.8) was ten time weaker than terreulactone A, while 11a-
dehydroxyisoterreulactone did not show any activity, which was in agreement with 
previous conclusion that α, β-unsaturated carbonyl and the 11a-OH group are important 
in the AChE inhibition activity.95, 105  
 
 
Figure 1.8. Structures of terreulactones. 
	  
1.6 Prospects for fungal natural product drug discovery 
In the past decade, many pharmaceutical companies have cut down or even 
abandoned their drug discovery research from natural sources due to their discovery 
model (quickly and profitably), and the difficulties in discovering drug candidates from 
natural sources.106 On the contrary, they shifted to high-throughput screening of synthetic 
libraries.107 This led to the declined of new drugs approvals.106 Despite that, there are still 
35% of approved drugs are nature products based.22 In addition, there are enormous 
natural resources that have not been explored, more than 85% of higher plant species,108 
99% of bacteria109 and 95% of fungi6. With the development of rapid genome sequencing, 
culture techniques as well as the development of high-throughput screening, more of 
these untapped sources will be explored. Moreover, the identification process of natural 
product drug discovery will be expedited by the development of the analytical techniques 
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in separation and structure elucidation. What’s more, synthetic biology offers a good 
opportunity for novel natural products discovery. Thus, I believe that natural product 
drug discovery will continue play a key role in drug discovery.	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Chapter 2: Chapter Overviews 
2.1 Hypothesis  
Estimates of fungal diversity reveals there are more unexplored fungi than those 
that have been investigated. In addition, fungal derived drugs are currently used in 
limited therapeutic areas including antibiotics, immunosuppressant, and cholesterol 
lowing agents. With the aim of discovering new fungal natural products for drug 
discovery, the hypothesis guiding my research was: accessing new fungal biodiversity is 
critical for identifying new bioactive secondary metabolites. This hypothesis was 
tested via the following specific aims:  
1.   Identification of candidate known-unknown fungal isolates (Genbank) from 
insufficiently described fungi, and the isolation of new compounds from a 
previously undescribed fungus. 
2.   Development of a high-throughput high-content screening assay for the human 
parasite Trichomonas vaginalis, discovery of tetramic acid derivatives as potent 
anti-trichomonas fungal metabolites and the isolation of tetramic acid derivatives. 
3.   Isolation of new meroterpenoids from a Penicillium sp. in the course of 
phenotype-based zebrafish screening. 
 
2.2 Chapter 3. Enhancing Natural Product Discovery Using a Rumsfeldian Matrix 
to Gauge Fungal Isolate Novelty from DNA-Barcode Data 
The kingdom Fungi is comprised of highly diverse taxa with an estimated of 2.2 - 
3.8 million species on earth, of which only 5% have been described so far. Morphological 
characterization and DNA barcoding have served as the major strategies in fungal 
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identification, with the latter considered as the universal tool. However, the DNA 
barcoding approach also suffers from certain weakness. One of the growing problems of 
is that more and more GenBank sequences accessions fall into the category of 
“insufficiently identified”. This has important implications for natural product chemical 
discovery since it is presumed that chemically unexplored fungal species are more likely 
to serve as sources of new natural products. In this chapter, we propose a schema for 
using ITS barcode data to mine GenBank and identify high priority fungal isolates as 
potential sources of new natural products. In addition, we conducted a chemical analysis 
of one high-priority fungal isolate demonstrating that most of its major metabolites were 
previously unreported natural products. 
 
2.3 Chapter 4. Creation and Application of a High-Throughput High-Content 
Screening Assay for Natural Product Inhibitors of the Human Parasite Trichomonas 
vaginalis 
In this chapter, a high-throughput high-content screening assay for the human 
parasite Trichomonas vaginalis along with a counter-screen for mammalian cell toxicity 
using the normal human cervical cell line Ect1/E6E7 were developed. Bioassay-guided 
purification of one active fungal isolate led to the discovery of a class of molecules, 
tetramic acid derivatives, which showed potency in the anti-trichomonas assay. This 
included the natural products equisetin (4.1), pyrrolocin A (4.4), and beauversetin (4.6), 
which showed tremendous promise as novel chemical leads. The isolation and structure 
elucidation of these compounds are discussed.  
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2.4 Chapter 5. Cholinesterase Inhibitory Arisugacins L-Q from a Penicillium sp. 
Isolate Obtained through a Citizen Science Initiative and their Activities in a 
Phenotype-Based Zebrafish Assay 
This chapter explores the use of a phenotype-based zebrafish assay for screening 
our fungal crude extract library. In addition, we report the isolation and structure 
elucidation of new compounds, as well as describe their acetylcholinesterase inhibitory 
activities. In the course of phenotype-based zebrafish screening of fungal crude extract 
library, one sample was found to impair zebrafish motility. Bioassay-guided purification 
led to the identification of 14 meroterpenoids including 6 new metabolites, arisugacins L-
Q, 7 known arisugacins and 1 known terreulactone. Their structures were elucidated 
using a combination of NMR and HRESIMS data as well as the theoretical and 
experimental ECD spectra and modified Mosher’s method. The purified compounds were 
tested in zebrafish embryos as well as in vitro for cholinesterase inhibition. 
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Chapter 3. Enhancing Natural Product Discovery Using a Rumsfeldian 
Matrix to Gauge Fungal Isolate Novelty from DNA-Barcode Data 
This chapter was adapted from a manuscript which is currently being prepared 
for submission in 2019. The authors are Wentao Dai, Jin Woo Lee, Karen Wendt, Fares 
Z. Najar, and Robert H. Cichewicz. 
The work presented in this chapter was conducted as follows: Wentao Dai 
performed DNA barcoding analysis; Jin Woo Lee performed extraction, purification and 
structure elucidation of compounds 3.1-3.13; Karen Wendt performed the isolation of 
fungal isolates and large-scale fermentations.  
 
3.1 Introduction 
The kingdom Fungi is comprised of highly diverse taxa that have adapted to 
exploit a wide-range of ecological niches. These organisms exhibit tremendous lifestyle 
variation and morphological plasticity ranging from single cell yeasts to macroscopic 
mushrooms.110 The size of fungi also varies considerably from very small (e.g., 
individual hypha of microscopic fungi can measure as little as ~2-10 µm in diameter) to 
immense (e.g., the largest organism on Earth is believed to be a clonal Armillaria ostoyae 
located in eastern Oregon, USA, which spans an area covering ~8.9 km2).111 Considered 
the second largest kingdom of eukaryotic life, fungi play essential roles in the 
environment, plant and animal health, and human welfare and disease.112-113 Despite their 
importance and ubiquity, the true extent of biodiversity within the kingdom Fungi 
remains unknown with estimates suggesting that perhaps as few as 5% of the world’s 2.2 
- 3.8 million fungi have been identified.37 
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As is the case in most fields of taxonomic inquiry, morphological features such as 
fruiting body characteristics and spore structures have long served as the principal means 
by which fungi were identified.43 The foundation for these approaches were laid down 
two and half centuries ago by the likes of Heinrich Anton de Bary, Christian Hendrik 
Persoon, and Elias Magnus Fries, who were among the first naturalist to apply 
macroscopic morphological characteristics, as well as qualitative microscopic 
observations to the systematic classification of fungi.114-115 While the field of mycology 
has adopted many additional tools (e.g., quantitative microscopy, electron microscopy, 
and others) that have aided in the morphological description and taxonomic classification 
of fungi,116-118 fungal systematics has remained heavily constrained by the limitations that 
morphological markers imposed on researchers trying to infer evolutionary relationships 
within the kingdom Fungi. Namely, the taxonomic assessment of fungi using only 
morphological metrics is complicated by several weaknesses that include (i) problems 
introduced through the convergent evolution of traits leading to polyphyletic groupings, 
(ii) the challenges of recognizing and deciphering the remarkable levels of intra- and 
inter-specific morphological plasticity exhibited by fungi, (iii) an abundance of asexual 
isolates that present rather indistinct physical features, and (iv) the vagaries of human 
interpretation introduced during the evaluation of these morphological traits. 
Fortunately, the postgenomic era has brought with it a suite of new and powerful 
molecular tools that have reshaped workflows used to identify fungi and have largely 
remodeled many fundamental aspects of fungal systematics. Perhaps the most powerful 
method to emerge is DNA barcoding, which has become a near universally applied tool 
for fungal identification.110 In general, DNA barcoding is performed by comparing a 
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fungus-derived DNA sequence against a repository of genomic data (e.g., GenBank) 
using the Basic Local Alignment Search Tool (BLAST). BLAST results contain both an 
identity value (sequence similarity) and percent query coverage (the degree to which the 
query and reference sequences match), which are used in combination to determine the 
taxonomic affinity of the fungus from which the DNA sequence originated. For fungi, the 
non-coding internal transcribed spacer (ITS) region is the most commonly employed 
portion of the fungal genome used for DNA barcoding48, 119 and it has been adopted as 
the official barcode for fungal identification.50 Details pertaining to the DNA-barcode-
based identification of fungi and best practices for its implementation have been 
reported.112, 120 
While DNA barcoding is an immensely powerful tool, this technique still suffers 
from certain weaknesses. For example, it has been estimated that nearly 70% of type 
strains have not been subjected to barcoding rendering them undetectable to sequence-
based searches.121 Moreover, sequence databases are thought to contain substantial 
numbers of errors (~20% may be misannotated in GenBank).122-123 Additional problems 
have been recognized including non-uniform rates of ITS diversification among fungi, 
the unintentional introduction of artifacts into barcodes due to sequencing errors, and 
others.124-125 Whereas the ease and simplicity of ITS barcoding has helped to democratize 
the process of fungal identification, the sheer number of problematic sequence records 
entering public databases has created new challenges for investigators. 
One of the growing problems of using DNA barcode data to identify fungi centers 
on the increasing number of GenBank sequences accessions that fall into the category of 
“insufficiently identified.”122-123, 126-127 This term generally refers to fungus-derived 
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sequence data for which no formal taxonomic assignment was made beyond the sub-
kingdom-level resulting in species annotations that include terms such as “Fungal sp.,” 
“Uncultured Ascomycete,” “Ascomycota sp.,” “Uncultured Ascomycota,” “Uncultured 
Soil,” and others. The problems posed by these types of annotations are two-fold: first, 
the abundance of GenBank entries described using only these terms serves to obscure the 
real taxonomic identities of fungi, and second, these imprecise labels complicate efforts 
to mine GeneBank for data supporting a fungal isolate’s phylogenetic novelty. This later 
point has important implications for natural product chemical discovery since it is 
presumed that chemically unexplored fungal species are more likely to serve as sources 
of new natural products as opposed to well-known organisms whose secondary 
metabolomes have been thoroughly investigated. In this report, we propose a schema for 
using ITS barcode data to mine GenBank and identify high priority fungal isolates as 
potential sources of new natural products. In addition, we conducted a chemical analysis 
of one high-priority fungal isolate demonstrating that most of its major metabolites were 
previously unreported natural products. 
 
3.2 Results and Discussion 
3.2.1 Conceptual Framework 
To identify fungal isolates with the highest probabilities of producing new natural 
products, our group developed a contextual framework for considering each isolate’s 
phylogenetic affinity (Figure 3.1). Inspiration for the design of this schema originate from 
a well-known quote given at a press conference by then United States Secretary of 
Defense Donald Rumsfeld: 
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“Reports that say that something hasn't happened are always interesting to 
me, because, as we know, there are known knowns; there are things we 
know that we know. There are known unknowns. That is to say, there are 
things that we now know we don't know. But there are also unknown 
unknowns. There are things we do not know we don't know” – U.S. 
Department of Defense News Briefing, February 12, 2002 
 
While this quote was the subject of significant comedic commentary, the idea 
behind this concept is thought to have been in circulation for some time and had been 
used in various manifestations of risk assessment strategies.128 Importantly, we believe 
that this conceptual scaffold can serve as a useful tool for considering the breadth of 
taxonomic knowledge available about a fungal isolates and help point investigators 
toward samples that have improved probabilities of yielding new natural products. 
Specifically, we hypothesize that the secondary metabolomes of many known fungi 
(known knowns, Figure 3.1) have been characterized partially or completely. In contrast, 
fungi that are new to the natural products community (known unknowns) may hold 
promise as the sources of new metabolites. Our experiences have led us to believe that 
unlike bacteria, the majority of fungi can be grown in the lab with existing methods, but 
have not yet been observed for one or more reasons unrelated to their respective 
culturability (e.g., fungal biological diversity far exceeds the mycological community’s 
capacity to culture and describe fungi, certain fungal habitats remain underexplored, low 
natural propagule abundance, highly localize fungal taxa, and others). Thus, focused 
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efforts to bring more known-unknown fungi into the lab presents tremendous promise for 
new natural products discovery. 
 
 
Figure 3.1. Contextual framework of each isolate’s phylogenetic affinity. 
	  
3.2.1.1 Unknown Unknowns 
Under our sorting system, all fungal propagules entering the lab that have yet to 
be subjected to taxonomic analysis, are considered unknown unknowns. In other words, 
unknown-unknown fungi optimistically represent the full extent of the hypothesized 
biodiversity thought to exist within the kingdom Fungi. Current estimates indicate that 
roughly 0.1-0.2 million fungal taxa have been formally described meaning 2.1-3.6 
million fungi have undergone no formal taxonomic analysis. In our view, these numbers 
imply that if one is interested in seeking yet-to-be described fungal taxa, then most 
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meaningful attempts to culture fungi from the environment should provide reasonable 
chances for encountering new taxa as an appreciable fraction of the total number of 
isolates observed. Once an unknown-unknown fungus has been brought into culture, it is 
important to subject the isolate to some form of identification that will enable its 
progression to one of three categories (i.e., known known, unknown known, and known 
unknown) based on the isolate’s proposed taxonomic affinity. In our view, ITS DNA 
barcoding represents the most practical and effective solution to rapidly evaluate large 
numbers of fungal isolates. The steep rise in the use of DNA barcoding throughout the 
mycological community coupled with its cost effectiveness and universal applicability to 
fungi has made this technique an attractive method, which we have adopted as the 
standard systematics tool for analyzing fungal isolates.129 In the following sections, we 
describe how DNA barcode data are applied for the provisional assignment of fungi to 
either known-known or known-unknown status, as well as identify limitations of our 
system that allow unknown-known fungi to masquerade as known knowns and known 
unknowns (Figure 3.1).  
 
3.2.1.2 Known-Knowns 
The first potential outcome from using ITS DNA-barcode data is that a sequence 
provides a strong indication that an isolate is a likely representative from a known taxon 
(a known known). The current consensus is that fungi sharing ≥97% ITS barcode 
sequence identity should be classified as the same taxon.130 Although adopting such a 
rigid cutoff value will invariably result in conflict with the realities of the wide range of 
sequence variation observed in nature, we agree that this breakpoint provides a good 
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starting point for initially assessing an isolate’s novelty. While we recognize that a DNA 
barcode alone is insufficient to definitively identify an isolate, we believe that in the 
context of sifting through thousands of isolates to find candidate fungi that are likely to 
produce new natural products, a high-quality DNA barcode offers a strong starting point 
for making a tentative taxonomic assignment that can be later vetted by morphological 
and/or additional molecular analyses (vide infra). 
 
3.2.1.3 Known Unknowns 
The second possible outcome is that an isolate presents a weak match to 
publically available ITS DNA barcode data (<97% sequence similarity). In our 
terminology, this type of isolate should be tentatively classified as a known unknown (i.e., 
the DNA barcode data indicate that the isolate represents a new candidate taxon). In our 
view, isolates falling into this category provide the highest theoretical value for the 
discovery of new natural products since these fungi are less likely to have been subjected 
to prior chemical investigation. In addition, we recognize a distinctive sub-group within 
the known unknowns, which has arisen as a function of the proliferation of metagenomics 
data entering public databases (e.g., GenBank). Specifically, an isolate may be assigned 
known-unknown status when it exhibits strong DNA-barcode homology with available 
ITS sequences, but the sequences are derived from uncultured organisms. There has been 
a tremendous upsurge of culture-independent microbial surveys occurring the world over 
covering every major (and many minor) environmental niches. Consequently, it is 
anticipated that more and more known-unknown fungi will be represented by ITS 
barcode data long before they enter into culture and are formally described. 
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3.2.1.4 Unknown Knowns 
The third potential outcome for an unknown-unknown fungal isolate is that ITS 
barcode data will lead to its mistaken assignment as a known known or known unknown. 
There are several possible ways that unknown knowns can be incorrectly assigned124-125 
and some of them are considered here. One of the major challenges of using an ITS-based 
barcode identification system is that a significant portion of the publically available data 
are not properly annotated or vetted resulting in sequences that are improperly attributed 
to an incorrect taxon. Another problem is that not all known fungi, including type strains, 
have been subjected to ITS sequencing resulting in gaps in our ability to accurately 
identify fungal isolates. In these situations, fungi may be identified as known unknowns 
when in fact the isolates represent a formally accepted species. Furthermore, the 
resolving power of ITS data is not equivalent across all taxonomic groups, which can 
limit species delineation. Finally, ITS data can be prone to certain technical errors that 
compromise the accuracy of taxonomic assignments; however, data quality surveillance 
measure can help to limit the impact of these error types. Unfortunately, most unknown 
known fungi will remain undetected until additional analysis methods are applied 
(morphological and/or additional molecular markers). 
 
3.2.2 Sourcing Fungal Isolates through Citizen Science 
The University of Oklahoma Citizen Science Soil Collection Program was 
launched in 2010 to secure chemically-diverse natural products made by fungi for the 
purpose of identifying bioactive compounds with applications to human and animal 
health.131 To date, 5914 of soil samples have been received from citizen scientist located 
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throughout the United States (Figure 3.2) and data derived from those samples have been 
made available through our open access data sharing platform on SHAREOK.131 Our 
barcoding method focuses on amplifying the non-coding ITS DNA using the ITS1F and 
ITS4 primers.120 This approach provides single-direction nucleotide sequence data for 
each fungus, which is used to establish an isolate’s provisional taxonomic affinity via 
BLASTN (nucleotide BLAST) with data archived in GenBank. While a DNA barcoding 
approach imposes certain constraints on the power and precision of the taxonomic 
assessments that are made, we have found our sequencing procedure to be financially and 
programmatically optimal since it provides an affordable, high-throughput solution to 
achieving reasonably high levels of accuracy. Throughput and biological diversity were 
two key considerations factoring into the development of our pipeline since a functional 
fungal drug discovery library requires large numbers of taxonomically diverse fungi that 
afford access to chemically diverse natural products. Based on that vision, our team has 
prepared 44,000 ITS barcoded isolates from citizen-science-submitted soil samples and 
we continue to add fungi to the collection at a rate of just under 1,000 isolates per month 
(e.g., 11,557 fungi were DNA barcoded in 2018). An analysis of the data indicates that 
our citizen-science-driven efforts are capturing reasonably high level of fungal diversity 
with at least 630 genera represented in our collection. Moreover, 4,100 (9.3%) of the 
isolates cannot be readily assigned a genus-level taxonomic affiliation, which suggests 
that the program is effective at securing fungal “dark matter” that has yet to scientifically 
described or chemically explored. An analysis of ITS data quality control descriptors 
revealed that a majority of the ITS data we have generated is composed of reads 
consisting of >400 base pairs with 90% of the data exhibiting phred scores of 40 or 
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higher (for reference, a phred score of 40 indicates a 99.99% probability that the bases in 
ITS sequences were called correctly) (Figure 3.3). 
 
 
Figure 3.2. Map of soil samples received from citizen scientists by the University of 
Oklahoma Citizen Science Soil Collection Program. 
	  
3.2.3 Analyzing the Impact of Insufficiently Identified Fungal Barcodes, Single 
Direction ITS Region Reads, and Secondary Molecular Taxonomic Marker Gene 
Data on Generating Genus-Level Taxonomic Assignments 
Informal observations within our group suggested that a substantial number of the 
fungi in our collection exhibited ITS barcode data with sequence homologies to 
insufficiently identified fungi (vide supra) based on BLASTN comparisons to sequence 
data archived in GenBank. Therefore, we carried out an experiment to better understand 
the magnitude of this phenomenon. We began with a random selection of 4,000 fungal 
isolates prepared between June 2014 and September 2016. It was during this period that 
our team codified its current fungal ITS DNA barcoding practices. BLASTN analyses 
were performed and the top 100 most similar GenBank accessions were recorded. To our 
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surprise, 264 (6.6%) of the isolates exhibited sequence similarity profiles in which at 
least the top 5 matches were to insufficiently identified fungi (i.e., the top 5 highest 
probability matches were given as one or a combination of the following terms “Fungal 
sp.,” “Uncultured Ascomycete,” “Ascomycota sp.,” “Uncultured Ascomycota,” and 
“Uncultured Soil”). Further analysis of these results provided a subdivision of these data 
revealing that 85 isolates (32.2% of insufficiently identified fungi) were labeled primarily 
as “Fungal sp.,” 14 isolates (5.3% of insufficiently identified fungi) were labeled 
primarily as “Uncultured Ascomycete,” 56 isolates (21.2% of insufficiently identified 
fungi) were labeled primarily as “Ascomycota sp.,”, 90 isolates (34.1% of insufficiently 
identified fungi) were labeled primarily as “Uncultured Ascomycota,” and 19 isolates (7.2% 
of insufficiently identified fungi) were labeled primarily as “Uncultured Soil.” Further 
consideration of the reasoning behind the use of these descriptors provided no clear 
indication for how or why each term was applied; however, it was observed that most of 
the sources used to generate the DNA sequence data that populated GenBank appeared to 
consist of sequences derived from metagenome datasets. In our view, these data have 
several intriguing implications beyond simply complicating ITS-barcode-based 
identification practices. Namely, the appearance of these types of matches provides a 
more comprehensive picture of a taxonomic unit’s prevalence in fungal communities, as 
well as offers an indication of its potential geographical reach. 
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Figure 3.3. Quality control metrics for fungal ITS barcode data associated with the 
University of Oklahoma Citizen Science Soil Collection Program. Distribution of (A) ITS 
barcode length and (B) phred scores for sequences in the collection. 
	  
The isolates were subjected to a second round of bidirectional sequencing of the 
ITS region, as well as sequencing of a secondary taxonomic marker gene, translation 
elongation factor 1-𝔞 (tef1).56	   Published	   reports	   have	   shown	   that	   tef1 has outstanding 
potential as a secondary fungal DNA barcoding tool that provides excellent taxonomic 
resolution that complements ITS barcodes.58 Further probing the data revealed that 95.1% 
of the isolates could be assigned with reasonable confidence to a probable genus when all 
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100 top BLASTN hits were considered (>95% sequence similarity scores). However, 4.9% 
of the isolates still showed low sequence homology (£95%) to data recorded in GenBank. 
These results suggest that while our general approach to the ITS barcode identification of 
isolates is reasonably accurate (10% of fungi were unresolved at the genus level using 
single direction read data versus 4.9% remaining unresolved using bidirectional ITS 
sequencing combined with tef1 sequence data), bidirectional sequencing coupled with 
employing a secondary molecular taxonomic marker provided increased power for 
resolving fungal taxonomic affinities. However, when balanced against the differences in 
cost and time invested, single direction read ITS barcode data are a practical and 
justifiable starting point for the generation of initial taxonomic descriptors for 
environmental fungal isolates. Importantly, this simplified approach served as an 
excellent tool for prioritizing candidate known-unknown fungi for follow-up 
investigations. 
 
3.2.4 Examining the Secondary Metabolome Features in a Candidate Known-
Unknown Fungus 
Based on data from our bioinformatics studies, we were highly motivated to 
explore whether the taxonomically difficult to define isolates could serve as sources of 
new natural products. While most natural product chemistry studies in our lab are 
bioassay-driven, we encountered a fortuitous set of circumstances wherein one of the 
taxonomically ill-defined fungal isolates we had investigated (internal code 74E10) had 
coincidently been identified as a hit that inhibited the growth of Mycobacterium 
tuberculosis. Upon fractionation of the crude organic extract from 74E10, the activity had 
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been lost, but its LC-ESIMS profile suggested it could serve as an interesting candidate 
for a chemically motivated natural products discovery investigation since only two of its 
major chemical constituents (3.1-3.13) (Figure 3.4) could be readily dereplicated could be 
readily dereplicated [deoxyphomalone (3.1)21 and monocerin (3.2)23,24]. Barcode data 
supported the asexual isolate’s assignment within the Phaeosphaeriaceae; however, 
comparisons of its ITS (91% sequence homology to a Pleosporineae sp.) and tef1 (95.3% 
sequence homology to a Bipolaris yamadae) data to GenBank sequences were unable to 
provide additional taxonomic resolution. Using our terminology (Figure 3.1), this isolate 
qualified as a known unknown. 
 
	  
Figure 3.4. Structures of fungal metabolites 3.1-3.13. 
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Compound 3.3 was isolated as an amorphous powder. Its molecular formula of 
C13H18O6 was established by HRESIMS (m/z 293.1007 [M+Na]+), indicating five degrees 
of unsaturation. The 1H NMR spectra of 3.3 showed signals for an aromatic proton at δH 
5.97, an methine at δH 4.19, an methoxy group at δH 3.84, two oxygenated methylenes at 
δH 3.53, four methylene protons at δH 3.25, 3.05 and 2.54 (2H) and one methyl group at 
δH 1.03. The 13C NMR and HSQC spectra exhibited 13 carbon signals including 
characteristic six aromatic carbon signals similar to those of phloroglucinol derivatives 
such as deoxyphomalone (3.1).132 The HMBC correlations from the protons of ethyl unit 
(H-5 and 6) to aromatic carbons (C-2′, 3′ and 4′) revealed this group was attached to C-
3′and the HMBC correlations from the methoxy protons to the C-6′ in the aromatic ring 
indicated that the methoxy group was located at C-6′ position. In addition, the presence of 
3,4-dihydroxy-buta-1-none moiety was confirmed by the 1H-1H COSY and HMBC 
correlations, and the weak long-range 1H-13C HMBC correlations between the aromatic 
proton and the ketone carbon established this C4 unit was attached to C-4′ (Figure 3.5). 
As a result, the above-mentioned process of the structure elucidation explained that it 
consisted of C2 (3′-ethyl group), C6 (phloroglucinol) and C4 (1′-butyl group) units. 
Absolute configuration of C-3 was determined as R ([α]9:; +20) by comparison with the 
optical rotation on the basis of the literature reporting (R)-3, 4-dihydroxy-1-phenylbutan-
1-one ([α]9:; +41.8) and its synthetic analogues.133 Therefore, the structure of 3.3 was 
determined as (3R)-3′-ethyl-2′,4′-dihydroxy-6′-methoxy-3,4-dihydroxybutyrophenone. 
	   34	  
	  
Figure 3.5. Key 1H-1H COSY, 1H-13C HMBC correlations for compounds 3.1. 3.3-3.7. 
 
Compound 3.4 was obtained as a white amorphous powder. The HRESIMS 
showed a sodiated molecular ion peak at m/z 291.0850 [M+Na]+ corresponding to 
molecular formula of C13H16O6, which indicated the presence of six degrees of 
unsaturation. The 1H and 13C NMR spectra of 3.4 (Table 3.1 and 3.2) suggested that 3.4 
shared the C2-C6-C4 skeleton with 3.3. The 13C NMR spectra of 3.4 (Table 3.2) showed 
signals for a carboxyl group at δC 175.9 and an additional methylene carbon at δC 28.0 
instead of two oxygenated carbons of 3.3. The HMBC correlations from H-3 to two 
ketones (C-1 and 4) indicated that a carboxyl group was located at the end of the 
butanone moiety (Figure 3.5). Thus, the structure of 3.4 was established as 3′-ethyl-2′,4′-
dihydroxy-6′-methoxy-4-carboxybutyrophenone. 
 
 
 
 
 
	   35	  
   Table 3.1. 1H NMR (400 MHz) Data for Compounds 3.3-3.7. 
	  
 
Compound 3.5 was obtained as a white amorphous powder. The molecular 
formula was established to be C13H14O5 based on HRESIMS (m/z 251.0922 [M+H]+). 
Analysis of its NMR spectra revealed that 3.5 carried typical C2-C6 units, but, its C4 unit 
was a characteristic moiety which was turned out to be an α,β-unsaturated-γ-
butyrolactone ring. The HMBC correlations from the protons in the lactone ring to C-1′ 
in the C6 unit, and the two singlet peaks at δH 6.23 and 4.48 suggested that C2-C6 unit 
was attached to C-1 in the lactone ring system (Figure 3.5). 
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     Table 3.2. 13C NMR (100 MHz) Data for Compounds 3.1 and 3.3-3.7.  
 
Compound 3.6 was isolated as green oil. Its 13C NMR and HRESIMS data 
indicated 3.6 had a molecular formula of C13H14O4 (m/z 235.0974 [M+H]+). The 1H and 
13C NMR spectra (Table 3.1 and 3.2) showed characteristic signals for an α-substituted 
furan ring at δH 6.49, 6.56 and 7.52, and δC 149.2, 108.6, 110.6 and 139.7 together with 
the signals corresponding to the C2-C6 units. Also, 1H-1H COSY correlations between H-
2 and H-3 and between H-3 and H-4 suggested that C4 unit formed five membered-ring 
with a couple of conjugated bonds (Figure 3.5).  
Compound 3.7 was obtained as a white amorphous powder. Its molecular formula 
was determined to be C15H20O6 from HRESIMS (m/z 319.1161 [M+Na]+). The 1H NMR 
and 13C NMR data (Table 3.1 and 3.2) were similar to those of deoxyphomalone (3.1) 
except for two additional methoxy group signals. Thus, the structure of 3.7 was 
determined to be 4,4′-dimethoxy-6-deoxyphomalone. 
No. 3.1a 3.3b 3.4b 3.5b 3.6b 3.7a 
1 206.1 203.0 202.9 167.0 149.2 203.0 
2 46.2 47.7 38.6 107.5 108.6 39.2 
3 18.2 68.5 28.0 179.3 110.6 28.4 
4 14.0 65.7 175.9 59.8 139.7 173.8 
5 15.5 14.9 14.9 15.4 15.7 15.4 
6 13.3 12.3 12.3 12.6 12.8 13.4 
1′ 105.8 104.6 104.2 107.0 99.0 105.4 
2′ 164.8 164.2 164.0 157.2 156.0 163.4 
3′ 109.5 110.0 109.9 110.2 110.5 112.1 
4′ 159.6 162.3 162.2 160.8 153.5 163.2 
5′ 90.1 89.8 89.7 95.3 91.0 85.7 
6′ 161.0 161.1 162.2 158.6 155.8 161.5 
4-OCH3 - - - - - 51.7 
4′-OCH3 - - - - - 55.4 
6′-OCH3 55.3 54.4 54.4 54.7 54.5 55.3 
aObserved in CDCl3. bObserved in MeOH-d4. 
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Table 3.3. 1H NMR (400 MHz) Data for Compounds 3.8-3.13 in MeOH-d4. 
No. 3.8  3.9 3.10 3.11 3.12 3.13 
3 4.51 (m) 5.07 (m) 5.15 (m) 5.09 (br s) 5.08 (br s) 5.07 (br s) 
4 4.71  (d, 2.8) 
4.63  
(d, 2.8) 
4.75  
(d, 2.8) 4.57 (br s) 4.57 (br s) 4.57 (br s) 
5 6.71 (s) 6.50 (s) 6.80 (s) 6.53 (s) 6.53 (s) 6.50 (s) 
9a 3.96  (d, 7.0) 2.58 (m) 2.62 (m) 2.68 (m) 2.69 (m) 2.72 (m) 
9b  2.16 (m) 2.21 (m) 2.10 (m) 2.07 (m) 2.06 (m) 
10 - 4.22 (m) 4.25 (m) 4.28 (m) 4.32 (m) 4.51 (br s) 
11a - 3.55  (d, 5.6) 
3.58  
(d, 5.6) 1.85 (m) 1.71 (m) 2.87 (m) 
11b    1.65 (m) 1.69 (m) 2.74 (m) 
12 - -  3.86 (m) 3.82 (m) - 
13 - -  1.18  (d, 6.0) 
1.18  
(d, 6.0) 2.15 (s) 
6-OCH3 3.95 (s) - 3.95 (s)    
7-OCH3 3.80 (s) 3.83 (s) 3.82 (s) 3.86 (s) 3.86 (s) 3.84 (s) 
 
Compound 3.8 was isolated as a white amorphous powder. Its molecular formula 
was assigned to be C12H14O7 based on the HRESIMS data (m/z 293.0642 [M+Na]+), 
indicating six degrees of unsaturation. The 1H and 13C NMR spectra of 3.8 (Table 3.3 and 
3.4) showed signals for an aromatic ring, two oxymethines, two oxymethylenes, two 
methoxy groups and a carboxylic carbon at δC 169.0. Analysis of the NMR data indicated 
3.8 had an isochroman-1-one skeleton that was shown in monocerin (3.2).134-135 The 
HMBC and 1H-1H COSY correlations of 3.8 suggested two hydroxyl groups were located 
at C-4 and 8 and two methoxy groups were assigned as C-6 and 7. Also, a hydroxymethyl 
group (-CH2-OH) was attached to C-3 in the isocoumarin moiety (Figure 3.6). The 
relative configuration of H-3 and 4 was defined as cis conformation by a ROESY 
experiment (Figure 3.7) and the absolute configuration was determined by using CD 
analysis. The CD spectrum of (R)-(-)-6-hydroxymellein and exserolides, which possess 
the dihydroisocoumarin moiety like 3.8, exhibited a negative Cotton effect at 270 nm 
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equivalent to the n→π* band. Since CD spectrum of 3.8 showed a negative Cotton effect 
at 270 nm, and the absolute configuration of 3.8 was assigned as 3R, 4R (Figure 3.8).136-
137  
Table 3.4. 13C NMR (100 MHz) Data for Compounds 3.2 and 3.8-3.13. 
No. 3.2a 3.8b 3.9b 3.10b 3.11b 3.12b 3.13b 
1 167.7 169.0 168.4 168.0 168.3 168.3 168.2 
3 
4 
81.2 82.2 81.1 81.3 81.5 81.6 81.5 
74.4 64.0 74.7 74.6 74.3 74.2 74.4 
4a 131.1 137.4 131.5 131.8 131.6 131.7 131.4 
5 104.3 102.9 109.7 104.7 108.9 109.0 109.1 
6 158.6 158.8 158.7 158.7 157.0 157.2 157.4 
7 137.2 136.2 135.7 136.7 135.4 135.5 135.6 
8 156.2 155.3 156.1 155.5 156.1 156.1 156.1 
8a 102.0 101.8 99.0 101.6 99.8 99.7 99.6 
9 38.9 60.3 35.3 35.2 38.7 39.1 38.6 
10 78.7 - 79.0 79.0 76.2 75.5 74.1 
11 38.0 - 64.2 64.1 44.9 45.3 49.3 
12 19.1 - -  64.9 64.4 207.7 
13 13.9 - -  21.9 22.8 29.0 
6-OCH3 56.2 55.4 - 55.4 - - - 
7-OCH3 60.0 59.5 59.3 59.5 59.4 59.4 59.4 
aObserved in CDCl3. bObserved in MeOH-d4. 
 
Compound 3.9 was obtained as colorless oil. The molecular formula of C13H14O7 
was established by HRESIMS (m/z 305.0644 [M+Na]+), indicating seven degrees of 
unsaturation. The 1D and 2D NMR data suggested the presence of an additional five 
membered ring that was also found in monocerin (3.2). The ROESY correlations between 
H-4 and H-3, H-3 and H-9α, and H-9α and H-10 indicated H-3, H-4, H-9α and H-10 
placed on the same face of the ring system (Figure 3.7). Therefore, the absolute 
configuration of 3.9 was determined as 3R, 4R and 10R according to its CD spectrum 
(Figure 3.8), which exhibited a negative Cotton effect at 270 nm, in the same way as 3.8.  
	   39	  
	  
Figure 3.6. Key 1H-1H COSY, 1H-13C HMBC correlations for compounds 3.8-3.13. 
 
Compound 3.10 was isolated as a white amorphous powder and its molecular 
formula was determined to be C14H16O7 based on the HRESIMS data (m/z 319.0800 
[M+Na]+). The 1H and 13C NMR spectra of 3.10 were very similar to those of 3.9 except 
for the presence of an additional methoxy group. These two methoxy groups were located 
at C-6 and C-7 like 3.2 by using the HMBC experiment. The absolute configuration of 
3.10 was also confirmed as 3R, 4R and 10R in the same manner as 3.8. 
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Figure 3.7. Key ROESY correlations for compounds 3.8-3.13. 
 
Compounds 3.11 and 3.12 were isolated as colorless oil and their molecular 
formula were the same as C15H18O7 from the HRESIMS data (3.11: m/z 333.0957 
[M+Na]+, 3.12: m/z 333.0956 [M+Na]+). The 1D and 2D NMR spectra (Table 3.3 and 3.4) 
were similar to monocerin (3.2) except for the absence of 6-methoxy group and the 
presence of 12-hydroxy group. The 1D and 2D NMR spectra of 3.11 and 3.12 were 
nearly identical, other than the 13C NMR resonance of C10-C13, suggesting that they 
were C12-epimers. In order to confirm, the modified Mosher’s method was carried out 
(Figure 3.9). Thus, the absolute configuration of C-12 of 3.11 was determined as 12S and 
that of 3.12 was 12R.138-139 
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Figure 3.8. ECD spectra of compounds 3.2 and 3.8-3.13. 
 
Compound 3.13 was obtained as a white amorphous powder. Its HRESIMS data 
(m/z 331.0800 [M+Na]+), revealed the molecular formula was C15H16O7, indicating eight 
degree of unsaturation. The 1H and 13C NMR data of 3.13 (Table 3.3 and 3.4) resembled 
those of 3.11 and 3.12 and the only difference between them was 3.13 had the ketone 
group (δC 207.7) instead of 12-hydroxyl group of 3.11 and 3.12. The relative and absolute 
configuration of 3.13 was assigned as 3R, 4R and 10R by the ROESY experiment and CD 
analysis in the above-mentioned way. 
 
	  
Figure 3.9. Analysis of modified Mosher’s method for 3.11 and 3.12. Δδ (δS - δR) values 
are shown. 
3.2
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3.3 Conclusion and Future Directions 
In summary, we proposed a schema for using ITS barcode data to mine GenBank 
and identify high priority fungal isolates as potential sources of new natural products. On 
the basis of our study, considering the cost and time invested, single direction read ITS 
barcode data are a practical and justifiable starting point for the generation of initial 
taxonomic descriptors for environmental fungal isolates. Importantly, this simplified 
approach served as an excellent tool for prioritizing candidate known-unknown fungi for 
follow-up investigations. In addition, we conducted a chemical analysis of one candidate 
known-unknown fungal isolate and eleven metabolites which were previously unreported 
have been isolated. This indicated that what we proposed is applicable. In the future, we 
are going to perform chemical investigation on more candidate known-unknown fungal 
isolates to testify the schema we proposed. In addition, morphological characterization 
and other DNA barcoding gene could be used for the identification of those candidate 
known-unknowns.  
 
3.4 Materials and Methods 
3.4.1 General Experimental Procedures 
Optical rotation measurements were made on an AUTOPOL® III automatic 
polarimeter. ECD spectra were obtained on a JASCO J-715 circular dichroism 
spectrometer. The LC-ESIMS analyses were performed on a Shimadzu UFLC system 
with a quadrupole mass spectrometer using a Phenomenex Kinetex C18 column (3.0 mm 
× 75 mm, 2.6 µm) and MeCN-H2O (0.1% HCOOH) gradient solvent system. HRESIMS 
spectra were measured using an Agilent 6538 Ultra High Definition (UHD) Accurate-
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Mass Q-TOF system. NMR spectra were obtained on Varian spectrometers (500 MHz for 
1H and 100 MHz for 13C) using MeOD-d4 and CDCl3-d as solvent. The preparative 
HPLC system was equipped with SCL-10A VP pumps and system controller and a 
Gemini 5 µm C18 column (110 Å, 250 × 21.2 mm). The semi-preparative HPLC were 
performed using Waters 1525 binary pumps coupled with Waters 2998 photodiode array 
detectors and Gemini 5 µm C18 columns (110 Å, 250 × 10 mm). PCR was performed 
using a Lightcycler® 480 Real-Time PCR and a PTC-200 Peltier Thermal Cycler 
instrument. All solvents were of ACS grade or better. 
 
3.4.2 DNA Extraction and Polymerase Chain Reaction (PCR) 
A total of 4000 isolates from our Citizen Science Soil Collection Program were 
cultured on the Czapek Ivermectin Agar (CZI), then subjected to DNA extraction and 
PCR. DNA extraction were carried out by mixing mycelium with magnetic beads in PBS 
solution (200 µL), then blended for 5 min, the supernatant is the DNA solution. PCR 
were done by using the primer ITS1F (20 µM) and primer ITS4 (20 µM) to amplify the 
nuclear ribosomal internal transcribed spacer (ITS). The cycling parameters for PCR 
were 40 cycles of 1min at 95ºC, 1min at 50ºC, l min at 72ºC. PCR products were 
sequenced reversely and all the sequence data were queried against GenBank using Basic 
Local Alignment Search Tool (BLAST). Second round PCR were done for forwardly 
sequence in order to generate longer sequences for fungal identification. Isolates were 
cultured in Malt Extract Broth (MEB), then subjected to DNA extraction by using the 
PowerLyzer Powersoil DNA Isolation Kit. The primers and the cycling parameters used 
are aforementioned the same. The primers used for tef1 PCR were EF1 1018F and EF1 
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1620R. And the cycling parameters were : 1. 94˚C - 2 min, 2. 66˚C - 56˚C touchdown (9 
cycles), 3. 94˚C -30 second, 4. 56˚C - 1 min, 5. 72˚C - 1 min, 6. Repeat 3-5 for 36 cycles, 
7. 72˚C - 10 min, 8. 4˚C on hold.112  
 
3.4.3 Extraction and Isolation of new compounds from the fungus 74E10 
The fungus was cultured on a solid medium composed of Cheerios with 0.3% 
sucrose solution with 0.005% chloramphenicol for four weeks at room temperature 
(25ºC).140 The fungal cultures were extracted with EtOAc (3×2L) at room temperature, 
and the EtOAc solution was evaporated in vacuo to obtain the crude extract (Fraction A, 
26 g). Fraction A was separated by silica gel vacuum column chromatography getting 
fraction B (Dichloromethane 100%), fraction C (Dichloromethane/MeOH = 10/1) and 
fraction D (MeOH 100%). Fraction C was also fractionated by HP20ss column 
chromatography obtaining five fractions, E (30% MeOH), F (50% MeOH), G (70% 
MeOH), H (90% MeOH) and I (100% MeOH). Fraction E was separated into five sub-
fractions (E1-5) by preparative HPLC (C18, 25 to 60% MeCN/H2O in 15 min, flow rate: 
10 mL/min) and subfraction E2 was further subjected to semi-preparative HPLC (C18, 
MeCN:H2O = 20:80, flow rate: 4 mL/min) to yield 3.8 (4 mg, tR = 8 min). Fraction F was 
also separated into eight subfractions (F1-8) by preparative HPLC (C18, 35 to 70% 
MeCN/H2O in 15 min, flow rate: 10 mL/min) and subfractions F3, F6 and F7 looked like 
a pure compound and they were turned out to be 3.3 (25 mg), 3.4 (240 mg) and 3.6 (10 
mg), respectively. Compounds 3.5 (1.5 mg, tR = 11 min) and 3.9 (2 mg, tR = 8 min) were 
purified from subfraction F1 by semi-preparative HPLC (C18, MeCN:H2O = 25:75, flow 
rate: 4 mL/min), and compounds 3.10 (2 mg, tR = 10 min), 3.11 (10 mg, tR = 11 min) and 
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3.12 (2 mg, tR = 12 min) were also isolated from subfraction F2 by semi-preparative 
HPLC (C18, MeCN:H2O = 25:75, flow rate: 4 mL/min). Subfraction F was processed by 
semi-preparative HPLC (C18, MeCN:H2O = 30:70, flow rate: 4 mL/min) to get 3.13 (3 
mg, tR = 8 min), and 3.2 (10 mg, tR = 10 min) was purified from fraction H by semi-
preparative HPLC (C18, MeCN:H2O = 60:40, flow rate: 4 mL/min). Fraction B was also 
fractionated into five fractions (J-N) by HP20ss column chromatography in the above-
mentioned way. Fraction M (90% MeOH) was further subjected to preparative HPLC 
(C18, 75 to 100% MeCN/H2O in 15 min, flow rate: 10 mL/min) getting two subfractions 
(M1 and M2), and 3.7 (7 mg, tR = 10 min) and 3.1 (1 mg, tR = 11 min) were isolated from 
subfraction M2 by semi-preparative HPLC (C18, MeCN:H2O = 70:30, flow rate: 4 
mL/min). 
Deoxyphomalone (3.1): white amorphous powder; 13C NMR (100 MHz, CDCl3), see 
Table 4; ESIMS m/z 239 [M+H]+. 
Monocerin (3.2): white amorphous powder; α 9:; +40.0 (c 0.1. MeOH); CD (MeOH) 
λmax (Δε) 213 (+24.4), 270 (-18.1) nm; 13C NMR (100 MHz, CDCl3), see Table 6; 
ESIMS m/z 309 [M+H]+. 
Compound 3.3: white amorphous powder; [α]9:; +16 (c 0.1, MeOH); UV (MeOH) λmax 
(log ε) 228 (8.7), 290 (6.6) nm; 1H NMR (400 MHz, MeOH-d4) and 13C NMR (100 MHz, 
MeOH-d4), see Table 3 and 4; HRESIMS m/z 293.1007 [M+Na]+ (calcd for C13H18NaO6, 
293.0996). 
Compound 3.4: white amorphous powder; UV (MeOH) λmax (log ε) 232 (2.0), 293 (2.8) 
nm; 1H NMR (400 MHz, MeOH-d4) and 13C NMR (100 MHz, MeOH-d4), see Table 3 
and 4; HRESIMS m/z 291.0850 [M+Na]+ (calcd for C13H16NaO6, 291.0839). 
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Compound 3.5: white amorphous powder; UV (MeOH) λmax (log ε) 202 (8.0), 221 
(5.5), 254 (6.5), 296 (2.2) nm; 1H NMR (400 MHz, MeOH-d4) and 13C NMR (100 MHz, 
MeOH-d4), see Table 3 and 4; HRESIMS m/z 251.0922 [M+H]+ (calcd for C13H15O5, 
251.0914). 
Compound 3.6: green oil; UV (MeOH) λmax (log ε) 230 (2.1), 276 (1.6) nm; 1H NMR 
(400 MHz, MeOH-d4) and 13C NMR (100 MHz, MeOH-d4), see Table 3 and 4; 
HRESIMS m/z 235.0974 [M+H]+ (calcd for C13H15O4, 235.0965). 
Compound 3.7: white amorphous powder; UV (MeOH) λmax (log ε) 236 (1.6), 291 (3.1) 
nm; 1H NMR (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3), see Table 3 and 4; 
HRESIMS m/z 319.1161 [M+Na]+ (calcd for C15H20NaO6, 319.1152). 
Compound 3.8: white amorphous powder; [α]9:;	  -18.0 (c 0.1, MeOH); UV (MeOH) 
λmax (log ε) 219 (7.0), 231 sh (5.7), 274 (4.5), 308 sh (1.3) nm; CD (MeOH) λmax (Δε) 
213 (+11.1), 271 (-17.8) nm; 1H NMR (400 MHz, MeOH-d4) and 13C NMR (100 MHz, 
MeOH-d4), see Table 5 and 6; HRESIMS m/z 293.0642 [M+Na]+ (calcd for C12H14NaO7, 
293.0632). 
Compound 3.9: colorless oil; [α]9:;	  +30.0 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 219 
(6.6), 231 sh (5.2), 273 (3.7), 308 sh (1.6) nm; CD (MeOH) λmax (Δε) 213 (+11.8), 271 
(-18.2) nm; 1H NMR (400 MHz, MeOH-d4) and 13C NMR (100 MHz, MeOH-d4), see 
Table 5 and 6; HRESIMS m/z 305.0644 [M+Na]+ (calcd for C13H14NaO7, 305.0632). 
Compound 3.10: white amorphous powder; [α]9:; +24.0 (c 0.1, MeOH); UV (MeOH) 
λmax (log ε) 221 (5.8), 230 sh (5.0), 273 (3.8), 308 sh (1.5) nm;  CD (MeOH) λmax (Δε) 
213 (+9.6), 271 (-7.8) nm; 1H NMR (400 MHz, MeOH-d4) and 13C NMR (100 MHz, 
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MeOH-d4), see Table 5 and 6; HRESIMS m/z 319.0800 [M+Na]+ (calcd for C14H16NaO7, 
319.0788). 
Compound 3.11: colorless oil; [α]9:;	  +22.0 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 
221 (5.4), 231 sh (4.7), 273 (3.8), 308 sh (1.7) nm;  CD (MeOH) λmax (Δε) 213 (+14.1), 
271 (-7.6) nm; 1H NMR (400 MHz, MeOH-d4) and 13C NMR (100 MHz, MeOH-d4), see 
Table 5 and 6; HRESIMS m/z 333.0957 [M+Na]+ (calcd for C15H18NaO7, 333.0945). 
Compound 3.12: colorless oil; [α]9:;	  +40.0 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 
221 (4.3), 231 sh (3.5), 273 (2.3), 308 sh (1.1) nm; CD (MeOH) λmax (Δε) 213 (+17.9), 
271 (-8.4) nm; 1H NMR (400 MHz, MeOH-d4) and 13C NMR (100 MHz, MeOH-d4), see 
Table 5 and 6; HRESIMS m/z 333.0956 [M+Na]+ (calcd for C15H18NaO7, 333.0945). 
Compound 3.13: white amorphous powder; [α]9:;	  +22.0 (c 0.1, MeOH); UV (MeOH) 
λmax (log ε) 221 (2.8), 231 sh (3.5), 273 (2.0), 308 sh (0.9) nm; CD (MeOH) λmax (Δε) 
213 (+13.5), 271 (-7.7) nm; 1H NMR (400 MHz, MeOH-d4) and 13C NMR (100 MHz, 
MeOH-d4), see Table 5 and 6; HRESIMS m/z 331.0800 [M+Na]+ (calcd for C15H16NaO7, 
331.0788). 
 
3.4.4 Preparation of the (S) and (R)-MTPA Mosher Ester Derivatives  
of 3.11 and 3.12	  
Compounds 3.11 and 3.12 (each 0.5 mg) were dissolved in pyridine-d5 (each 1 
mL) with a small amount of 4-(dimethylamino)-pyridine (DMAP) and were transferred 
into NMR tubes. (S)-(+)-α-methoxy-α-(trifluoromethyl)-phenylacetyl (MTPA) chloride 
(10 µL) were added into the NMR tubes under a N2 gas stream, and then the NMR tubes 
were shaken to make sure the samples were mixed. The NMR tubes were placed in a 
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water bath for 6 h (40°C), which afforded (R)-MTPA ester derivatives (S)-MTPA ester 
derivatives were also yielded in the same way as the procedure mentioned above, using 
(R)-(-)-MTPA chloride. The 1H and 1H-1H COSY spectra were directly obtained from the 
MTPA ester derivatives of 3.11 and 3.12. 
(R)-MTPA ester of 3.11: 1H NMR (500 MHz, pyridine-d5) : δH 5.44 (1H, br s, H-12), 
5.21 (1H, br s, H-3), 4.76 (1H, s, H-4), 4.16 (1H, br s, H-10), 2.53 (1H, m, H-9), 2.16 (1H, 
m, H-9), 2.13 (1H, m, H-11), 1.81 (1H, m, H-11), 1.31 (3H, br s, H-13). 
(S)-MTPA ester of 3.11: 1H NMR (500 MHz, pyridine-d5) : δH 5.45 (1H, br s, H-12), 
5.30 (1H, br s, H-3), 4.87 (1H, s, H-4), 4.31 (1H, br s, H-10), 2.63 (1H, m, H-9), 2.15 (1H, 
m, H-9), 2.12 (1H, m, H-11), 1.79 (1H, m, H-11), 1.15 (3H, br s, H-13). 
(R)-MTPA ester of 3.12: 1H NMR (500 MHz, pyridine-d5) : δH 5.40 (1H, br s, H-12), 
5.26 (1H, br s, H-3), 4.94 (1H, s, H-4), 4.39 (1H, br s, H-10), 2.58 (1H, m, H-9), 2.08 (1H, 
m, H-9), 1.90 (2H, m, H-11), 1.14 (3H, br s, H-13). 
(S)-MTPA ester of 3.12: 1H NMR (500 MHz, pyridine-d5) : δH 5.35 (1H, br s, H-12), 
5.23 (1H, br s, H-3), 4.87 (1H, s, H-4), 4.08 (1H, br s, H-10), 2.37 (1H, m, H-9), 1.97 (1H, 
m, H-9), 1.82 (2H, m, H-11), 1.17 (3H, br s, H-13). 
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Chapter 4: Creation and Application of a High-Throughput High-
Content Screening Assay for Natural Product Inhibitors of the Human 
Parasite Trichomonas vaginalis 
This chapter was adapted from a manuscript which has been submitted to ACS 
Infectious Disease.The authors are Jarrod King, Adam C. Carter, Wentao Dai, Jin Woo 
Lee, Yun-Seo Kil, Lin Du, Sara K. Helff, Brandt Huddle, Andrew N. Miller and Robert H. 
Cichewicz. 
The work presented in this chapter was conducted as follows: Jarrod King 
conducted the assay development and bioassay; Wentao Dai, Jin Woo Lee, Yun-Seo Kil 
and Lin Du performed extractions, purifications and structure elucidation of all the 
tetramic acid derivatives 4.1-4.9.  
 
4.1 Introduction 
Trichomonas vaginalis is the most frequently encountered sexually-transmitted 
parasite in the United States.141 Those infected by the parasite exhibit an increased risk 
for (i) HIV infection, (ii) development of cervical cancer, and (iii) infertility, as well as 
(iv) adverse pregnancy outcomes including (iv) miscarriage and (v) low-preterm birth 
weight.142 Current clinical treatment options are limited to antiprotozoal nitroimidazoles 
(i.e., metronidazole and tinidazole), which still offer appreciably high levels of clinical 
efficacy (>90% of patients are cleared of the infection after a single course of 
treatment)143-145. However, concerns haves arisen that in addition to several noted side 
effects (e.g., nausea, vomiting, and others), the nitroimidazoles may possess carcinogenic 
and mutagenic properties.146-147 This has led to worry about nitroimidazole treatment 
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during pregnancy, as well as some apprehension about their use in the general 
population.146 A rather troubling problem, which came to light based on surveillance data 
collected from patients infected with T. vaginalis receiving standard courses of 
nitroimidazole treatment, is the high rate of infection recurrence (5-31% in women).145 
While a portion of disease recurrence is attributable to further contact with untreated 
sexual partners, data suggest that a portion of T. vaginalis cases have the capacity to 
develop into persistent infection states, which raises concerns about the clinical 
limitations of nitroimidazole therapies.148 Even more concerning, nitroimidazole 
resistance has been detected in up to 9.6% of clinical T. vaginalis isolates raising 
concerns that nitroimidazoles might become clinically less effective.149-150 Considering 
the noted safety concerns and troubling clinical observations, there is a need for new 
disease management options that extend beyond the nitroimidazoles for treating T. 
vaginalis infections. 
An examination of the research literature has revealed surprisingly sparse 
information concerning efforts to identify new classes of antiprotozoal molecules active 
against T. vaginalis with only a small fraction of those endeavors dealing with natural 
products.151-152 A handful of prior studies had focused exclusively on testing plant 
extracts,153-156 but revealed little about the molecules responsible for their inhibitory 
effects. In a few instances, chemically-driven investigations of plant extracts have yielded 
a handful of secondary metabolites possessing activity against T. vaginalis including 
berberine,157 (-)-usnic acid,158 emodin,159 hamycin,160 hederagin,161 and mulinolic acid;162 
however, these compounds suffer from poor potency and lack selectivity compared to 
metronidazole. Although the limited scope of reports pertaining to the discovery of new 
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leads to fight T. vaginalis infections is worrisome, it also signals the potential that may 
exist to identify new bioactive compounds for development into clinically useful agents. 
This expectation is reasonable, especially for natural products, which have long served as 
an outstanding resource for the discovery of new antiinfectious agents163 including the 
topmost antiparasitic compounds in current clinical use (e.g., avermectins, artemisinin, 
and more).163-164 
Aside from the scarcity of natural-product-focused drug discovery efforts focused 
on inhibition of T. vaginalis, there are relatively few reports of vetted assay methods that 
are amendable to the systematic screening and identification of compounds that inhibit 
this unique parasite. Most of the reported methods had employed microscopy-based 
approaches for cell enumeration165 or used metabolically-activated dyes such as resazurin 
as indicators of parasite viability.166-167 With this in mind, we set about developing an 
assay system that was (i) able to robustly identify antitrichomonal compounds, (ii) 
amenable to high-throughput sample testing, (iii) could accurately distinguish between 
complete versus partial inhibition of the T. vaginalis, and (iv) could be used on a wide 
variety of sample types including pure compounds and natural product extracts. Herein 
we report the results of our assay development program, as well as describe new natural 
product scaffolds that exhibit promising inhibitory activities against T. vaginalis. 
 
4.2 Results and Discussion 
4.2.1 Development of an Assay for Detecting T. vaginalis Inhibitors 
Resazurin-based colorimetric assays are widely used in bioactive compound 
screening campaigns to identify substances that inhibit cell viability and proliferation 
under aerobic and anaerobic conditions.168 This dye and its water soluble salts are readily 
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reduced by NADH to yield the red, fluorescent product resorufin. Despite its reported use 
for detecting T. vaginalis inhibitors, we were surprised to discover that, in our hands, this 
reagent was rather insensitive for the detection of low numbers of viable cells. We 
observed that under anaerobic assay conditions, a population of ~10,000 trichomonads 
per well in a 96-well microtiter plate was needed as a threshold to consistently signal a 
positive response for the presence of live T. vaginalis. Given that we established an 
inoculum of 40,000 trichomonads per well as an optimal starting point for assays, it 
meant that compounds affording modest (~75%) parasite-kill rates would be 
indistinguishable from more potent and potentially better agents (Figure 4.1). Therefore, 
we set about designing a new assay system that was more sensitive, as well as able to 
handle a wide-range of complex test substances (e.g., pure compounds and extracts 
containing colored or fluorescing natural products). 
	  
	  
Figure 4.1. A comparison of the traditional resazurin fluorescence assay (red squares) 
and the newly developed imaging-based assay (green trangles). Using two fields per well, 
the Operetta’s limit of detection was 1,000 trichomonades per well. The limit of detection 
is bounded on the lower end by whether a trichomonad appears in an image field. 
Resazurin assay was unable to detect less than 10,000 organisms per well. 
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One method deemed to be a promising alternative to the resazurin assay was high-
content imaging.169 We speculated that this approach would offer a more responsive tool 
for evaluating the live/dead-status of virtually every trichomonad within a sample 
population. However, we quickly recognized that live trichomonads were not compatible 
with imaging-based detection methods; the rapid movements of the flagellated parasites 
cause each cell to severely blur even with reasonably fast exposure times (10 ms). 
Accordingly, we identified a method to fix the trichomonads with glutaraldehyde 
followed by the application of a dual cell-staining system consisting of acridine orange 
(cell-permeable DNA stain) and propidium iodide (DNA stain that is not permeant to live 
cells) for live/dead determination (Figure 4.2). Initial tests conducted using the Operetta 
(PerkinElmer) high-content imaging system revealed that this assay was capable of 
detecting as few as one live or dead trophozoite per image field and was robust (Z-factor 
of 0.92). Moreover, this type of detection system was amenable to high-throughput 
screening of T. vaginalis viability, especially with UV/Vis-active natural products since 
the stored image files (i.e., two image fields recorded per well) could be manually 
inspected to identify potential false-positive and false-negative results. 
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Figure 4.2. A. Sample field from the Operetta of a fixed and stained (0.5% 
glutaraldehyde, 2.5 µM propidium iodide, and 2.5 µM acridine orange) healthy growing 
population of trichomonas vaginalis at 17hr. One dead (red) trichomonad can be seen. B. 
Sample screening image from the Operetta showing partial inhibition from a fungal 
extract at 17hr. 
 
4.2.2 Testing Purified Natural Products 
To examine the probative capabilities of the new T. vaginalis imaging-based 
assay, a focused library of chemically diverse natural products was tested. The compound 
library consisted of 430 metabolites sourced by our research team from marine organisms, 
plants, bacteria, and fungi. An initial high-dose concentration (100 µM) was chosen so as 
to afford the opportunity to evaluate several challenging screening scenarios, especially 
those involving potential false-positives brought about by compound precipitation and 
UV/Vis-interference. The imaging-based assay proved invaluable since all the data files 
for potential hits (i.e., compounds that provided inhibition exceeding that afforded by 25 
µM metronidazole) were immediately available for inspection to confirm that the number 
of live trichomonads had been reduced. This test revealed that 64 of the natural products 
we tested exhibited activities that were equal to or better than the positive control. The 
large number of active samples was not unexpected since our pure compound library 
largely contained bioactive substances that had previously demonstrated cytotoxicity 
toward mammalian cells and/or inhibited the proliferation of microorganisms. To refine 
A B
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the list of natural products further, the hit compounds were screened at 25 µM, which 
resulted in a subset of 9 compounds that exhibited activities comparable to 25 µM 
metronidazole. These results also reinforced the need for a mammalian cell-based 
cytotoxicity counter screen to aid in the elimination of undesirable non-specific cellular 
toxins. Accordingly, the 9 hits were subsequently tested over a wide-range of 
concentrations extending two-orders of magnitude (0.25-25 µM) against both T. vaginalis 
and a normal mouse fibroblast (NIH/3T3) cell line. With these data in hand, the EC50 
values for all compounds against both the parasite and mammalian cells were estimated. 
The EC50 values were used to calculate a selectivity index (SI) value [SI3T3 = (EC50 for 
3T3 cells)/(EC50 for T. vaginalis)] for each of the bioactive substances (Figure 4.3). 
While the SI values revealed that most of the pure natural products were equipotent 
inhibitors of trichomonads and mammalian cells, one noted exception was 2-
bromoascididemine, which exhibited modest selectivity (SI3T3 = 14). Thus, we 
established that the new assay was amendable to the testing of structurally diverse natural 
products across a wide range of concentrations; furthermore, it could reveal each 
substance’s ability to selectively inhibit the target parasite. 
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Figure 4.3. Nine of 430 pure natural products evaluated for SI3T3 values in initial 
pure compound screening against T. vaginalis. Compound sources were diverse 
and are shown under the compound names. EC50 values were determined in T. 
vaginalis and 3T3 mammalian cells to obtain the SI3T3 values shown. Notably, 2-
bromoascididemin exhibited a SI3T3 value of 14.0, which was much higher than 
any of the other compounds tested. 
	  
4.2.3 Testing Fungal Natural Product Extracts 
The University of Oklahoma, Natural Products Discovery Group has generated a 
library of over 50,000 fungal extracts. Each extract consists of the organic residue 
obtained after a fungal isolate was cultured in small scale for 3 weeks on Cheerios 
breakfast cereal, extracted with ethyl acetate, and partitioned against water. For testing 
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purposes, a subset of 1,748 samples was selected for examination in the high-content-
imaging assay system. For the first stage of testing, we determined that it was most 
efficient to screen extracts in duplicate at a single concentration (15 µg/mL). This 
provided 111 ‘hits’ that inhibited the viability of T. vaginalis at levels equal to or better 
than the inhibition achieved using 25 µM metronidazole. These ‘hit’ extracts were 
subjected to a second stage of testing over a range of concentrations (0.15-15 µg/mL), 
which yielded 71 samples that retained potent activity and generated sigmoidal 
concentration-response curves. During this period in the assay development process, we 
considered the value of introducing a second mammalian cell selectivity evaluation since 
fibroblasts cells, although capable of vigorous in vitro growth that made them simple to 
test, might not offer the level of cytotoxin sensitivity or cellular properties typically found 
at the site of T. vaginalis infections. Thus, Ect1/E6E7 normal-type cervical cells were 
chosen to provide a second point of reference during selectivity testing. Accordingly, the 
EC50 values for each extract’s parasite-inhibitory activity, as well as its cytotoxic effects 
toward Ect1/E6E7 cells were determined and the data were plotted as illustrated in Figure 
4.4. This data visualization method provided a simple graphical tool to identify samples 
that offered the best selectivity for inhibiting parasites, yet exhibited limited toxicity 
toward mammalian cells. Thus, we proceeded to prioritize samples appearing in the upper 
right quadrant of the graph since those samples offered the best starting points for new 
bioactive compound discovery.  
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Figure 4.4. Selectivity index of 71 fungal crude extract library hits with activity better 
than 25 µM metronidazole. 
	  
4.2.4 Bioassay-Guided Purification and Testing of Natural Products from the 
Fusarium sp. Isolate B 
A crude extract prepared from the Fusarium sp. isolate was subjected to bioassay-
guided fractionation using silica gel vacuum liquid chromatography (VLC), HP20SS 
VLC, and C18 HPLC to afford the compound equisetin (4.1) (Figure 4.5). In the process 
of obtaining 4.1, 5¢-epiequisetin (4.2) (Figure 4.5) was also purified from the extract since 
its LC-ESIMS data had provided evidence that it was a likely structural analog of the 
bioactive constituent. The purified compounds were identified by comparison of their 1H 
and 13C NMR spectra and HRESIMS data to published values.170 The absolute 
configurations of the tetramic acid protions of both compounds were determined using a 
previously described oxidative bond-cleavage and LC-ESIMS analysis methodology.171-
172 Testing of the purified compound immediately revealed a stark difference in their 
respective antitrichomonal activities; whereas 4.1 exhibited rather potent inhibitory 
effects (EC50 = 3 µM) with good selectivity (SI = 33), 4.2 was inactive at a concentration 
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as high as 25 µM. An examination of both metabolites revealed that the remarkable 
difference in their biological activities could be traced to the inversion of single 
stereocenter (5¢S in 4.1 and 5¢R in 4.2). Taking these data into consideration, as well as 
considering the fact that 4.1 was non-toxic to L acidophilus at concentrations up to 50 
µM (Table 4.3), there was ample reason to believe that further exploration of this unique 
class of natural products had the potential to provide additional bioactive analogs. 
 
	  
Figure 4.5. Structures of compounds 4.1-4.9. 
 
To facilitate the identification of other natural products containing a tetramate 
linked to a trans-decalin system, we turned to our extensive library of fungal isolates and 
their associated chemical data. This family of natural products has been reported from a 
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taxonomically diverse assemblage of fungi171, 173-177 and our records revealed that we had 
previously encountered these compounds from several fungal isolates in our collection. 
After considering the range of metabolites anticipated from each candidate isolate, a list 
of four fungi was chosen to serve as the subjects of chemically-guided targeted isolation 
process: (i) Fusarium sp. isolate C, (ii) Penicillium sp., (iii) Alternaria sp., (iv) Phoma sp. 
P34E5. Those efforts led to the purification of seven additional tetramic acid derivatives 
trichosetin (4.3)175, pyrrolocin A (4.4),171 5¢-epipyrrolocin A (4.5) (new), beauversetin 
(4.6),176 5¢-epibeauversetin (4.7) (new), phomasetin (4.8),177 and 5¢-epiphomasetin 
(4.9)177 (Figure 4.5 and Table 4.3). Whereas the previously reported tetramic acid 
metabolites were identified based on comparisons of their mass spectrometry and 
spectroscopy data to published data, the new analogues became the foci of structure 
determination efforts. 
Compound 4.5 (purified from the Penicillium sp. isolate) was obtained as a pale 
yellow solid. Its molecular formula was deduced from HRESIMS data to be C27H39NO5 
([M-H]- ions at m/z 456.2747, calcd for 456.2747). The 1H (Table 4.1) and 13C (Table4.2) 
NMR data revealed the presence of eight olefinic carbons, an oxygenated methylene, an 
oxygenated methine, and five methyl groups. Comparison of the 1D NMR data of 4.5 
with compound 4.4 (isolated from the same fungus) indicated that the only noteworthy 
difference in the 13C NMR data for these two molecules was the carbon spin resonating at 
δC 68.1 in compound 4.4 now appeared at δC 67.4 in metabolite 4.5. Combining this 
information with the bond-line structure established for 4.5 (based on analyses of its 1H-
1H COSY, HSQC, and HMBC data summarized in Figure 4.4), it was proposed that the 
new natural product was the 5¢-epimer of 4.4. 
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Figure 4.6. A: 1H-1H COSY, HMBC and ROESY correlations of compounds 4.5. B: 1H-
1H COSY, HMBC and ROESY correlations of compounds 4.7. 
 
Upon probing the stereochemical properties of compound 4.5, the relative 
configuration of the decalin system was affirmed based on 1H-1H ROESY correlations 
detected between the following sets of protons: Me-12 ↔ H-6 and H-3; H-10a ↔ H-6, H-
7b, and H-8; as well as H-7a ↔ H-10b and H-11 (Figure 4.6A). The absolute 
configuration of this moiety was determined by comparing its CD spectrum with data 
obtained for similar metabolites. Specifically, the positive Cotton effects at 234 and 291 
nm indicated that the absolute configuration of the decalin-ring portion of this structure 
was 2R,3S,6R,8S,11S (Figure 4.7).171 The absolute configuration of the hydroxy group on 
the olefinic side chain was determined as 18R by using the modified Mosher reaction 
(Figure 4.8).138, 171 The absolute configuration of C-5' was determined by oxidative bond 
cleavage of the tetramic acid ring followed by acid bydrolysis to yield N-Me-serine.171-172 
Marfey derivatization of the N-Me-serine was performed and the product was analyzed 
by LC-ESIMS together with the derivatized hydrolytic products generated from N-Me-L 
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and D-serine standards. N-Me-D-serine was made by racemization of commercially 
available N-Me-L-serine using acetic acid and salicylaldehyde as described 
previously.178-179  The resulting amino acid residue was determined to be N-Me-L-serine, 
thus, the absolute configuration of 4.5 was assigned as 2R, 3S, 6R, 8S, 11S, 18R, 5'S. 
 
	  
Figure 4.7. CD Spectra of compound 4.5 and 4.7. 
	  
Compound 4.7 was purified as a pale yellow solid. Its molecular formula was 
deduced as C24H33NO4 based on HRESIMS data. The 1H NMR spectrum of 4.7 (Table 
4.1) showed thirty-one proton signals including five aromatic protons and four methyl 
spins. The 13C NMR spectrum (Table 4.2) contained twenty-four carbon spins, which 
were later classified according to their multiplicities using HSQC. Those data indicated 
that 4.7 was structurally similar to 4.5. Based on 2D NMR (1H-1H COSY, HSQC, and 
HMBC) data (Figure 4.6B), the bond-line structure of 4.7 was confirmed to be the same 
as metabolite 4.6, which indicated that two compounds were likely to be another set of 5' 
epimers. 
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 Table 4.1.1H NMR data for compounds 4.4-7 in DMSO-d6 (δ ppm).      
	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. δH (J in Hz) 
4.4a 4.5a 4.6b 4.7b 
3 3.13, m 3.25, m 3.20, m 3.21, m 
5 5.19, s 5.17, s 5.19, s 5.17, s 
6 1.76, m 1.78, m 1.79, m 1.78, m 
7 0.82, m 
1.79, m 
0.81, m 
1.77, m 
0.80, m 
1.77, m 
0.80, m 
1.77, m 
8 1.49, m 1.48, m 1.48, m 1.48, m 
9 1.02, m 
1.70, m 
1.00, m 
1.70, m 
1.01, m 
1.70, m 
0.97, m 
1.70, m 
10 0.99, m 
1.89, m 
0.98, m 
1.90, m 
0.95, m 
1.93, m 
0.94, m 
1.93, m 
11 1.57, m 1.57, m 1.54, m 1.53, m 
12 1.33, s 1.36, s 1.33, s 1.35, s 
13 5.22, m 5.16, m 5.15, m 5.11, dd 
(10.4, 14.7) 
14 5.71, m 5.79, m 5.72, dd 
(10.5, 14.7) 
5.78, dd 
(10.5, 14.7) 
15 5.88, m 5.82, m 5.90, dd 
(10.5, 13.7) 
5.86, dd 
(10.5, 13.7) 
16 5.50, m 5.46, m 5.50, m 5.46, m 
17 2.00, m 
2.09, m 
1.99, m 
2.08, m 
1.63, d (6.5) 1.62, d (6.5) 
18 3.57, m 3.57, m 1.52, s 1.51, s 
19 0.98, d 
(6.0) 
0.98, d (6.0) 0.88, d (6.3) 0.88, d (6.3) 
20 1.52, s 1.52, s   
21 0.88, d 
(6.5) 
0.88, d (6.5)   
1’   9.25, s 9.05, s 
5’ 3.75, br s 3.71, m 3.80, br s 3.78, br s 
6’ 3.81, d 
(11.0) 
3.69, m 
3.81, m 
3.72, m 
3.63, dd (2.1, 
11.0) 
3.59, m 
3.67, dd (2.1, 
11.0) 
3.61, m 
N-Me 2.92, s 2.91, s 2.92, s  
 
    aRecorded at 500MHz, bRecorded at 400MHz 
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Table 4.2. 13C NMR data for compounds 4.4-4.7 in DMSO-d6 (100 MHz, δ ppm) 
No.  δC   
4.4 4.5 4.6 4.7 
1 195.9 196.5 199.0 199.0 
2 49.0 49.6 49.2 49.5 
3 49.2 48.6 48.5 48.1 
4 131.3 131.9 131.4 131.6 
5 126.4 126.1 126.0 125.7 
6 39.1 39.2 38.7 38.7 
7 42.4 42.5 42.1 42.2 
8 33.3 33.4 33.0 33.0 
9 35.8 35.9 35.5 35.5 
10 28.1 28.1 27.6 27.7 
11 39.4 39.9 39.3 39.3 
12 14.0 14.2 13.4 13.5 
13 130.9 131.4 130.5 130.6 
14 132.7 133.0 132.1 132.5 
15 131.8 132.0 131.1 131.6 
16 130.9 130.5 128.0 127.7 
17 42.7 42.8 17.8 17.9 
18 66.3 66.3 22.2 22.3 
19 23.5 23.5 22.5 22.5 
20 22.6 22.7   
21 22.8 22.9   
2’ 176.6 175.8 179.2 179.0 
3’ 100.9 101.6 99.4 99.8 
4’ 190.9 190.5 190.7 190.6 
5’ 68.1 67.4 63.2 62.9 
6’ 58.4 58.6 60.8 60.7 
N-Me 27.2 27.3   
	  
The relative configuration of the decalin moiety was deduced as 
2R*,3S*,6R*,8S*,11S* based on the key 1H-1H ROESY correlations between H-3 ↔ Me-
12 and H-6, H-6 ↔ H-9b, as well as H-11 ↔ H-7a and H-9a (Figure 4.6B). The positive 
CD cotton effects of 4.7 at 234 and 289 nm indicated that the absolute configuration of 
the decalin moiety in 4.7 was the same as what occurred in 4.6 (Figure 4.7). Further 
analysis of the key ROESY correlations including H-13 and H-15 ↔ H-13 and Me-17 
revealed both exocyclic olefins (∆13 and ∆15) had trans geometries. Using the same 
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oxidative bond cleavage and LC-ESIMS analysis method that had been applied to the 
tetramic acid moiety in metabolite 4.5, the absolute configuration of C-5′ were 
determined as 5′R (4.6) and 5′S (4.7), respectively.171-172, 180 Thus, the absolute 
configuration of 4.7 was determined to be 2R, 3S, 6R, 8S, 11S, 5′S. 
 
	  
Figure 4.8. ΔδS-R values obtained in pyridine-d5 of the MTPA ester of compound 4.5 
 
	  
Figure 4.9. Effect of beauversetin on the growth of Trichomonas vaginalis in 
atmospheres of differing oxygen levels. Numbers shown are calculated from two fields in 
each well, three replicate wells per condition. 
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Table 4.3. Summary of tetramic acid derivatives: compound source, bioassay results and 
the corresponding selectivity index value. 
 
 
4.2.5 Biological Evaluation of Tetramic Acid Derivatives 
The antitrichomonal effects of the tetramic-acid-containing natural products were 
evaluated revealing an intriguing trend; whereas none of the 5'-epi compounds were 
active even at 25 µM. Compounds 4.1, 4.3, 4.4, 4.6 and 4.8 showed good activities with 
EC50 values at or below single digit micromolar concentrations. The three most potent 
molecules, 4.4 (EC50=0.060 µM), 4.6 (EC50=0.80 µM), and 4.8 (EC50=0.35 µM)	    showed 
strongest activities and were among the most potent T. vaginalis inhibitors we had 
observed to date. To determine if the Trichomonas-inhibitory effects of the tetramic acid 
natural products were affected by the presence of oxygen, metabolite 4.6 was tested 
under aerobic, microaerophilic, and anaerobic conditions and it maintained potency under 
all the tested atmospheric conditions (Figure 4.9). Although some tetramic-acid-
containing have been reported to possess antibacterial activities,181-182 none of the 
compounds that inhibited T. vaginalis inhibited L. acidophilus at 50 µM (Figure 4.10). 
The selectivity of the tetramic-acid metabolites for T. vaginalis versus mammalian cells 
also appeared favorable (Table 4.3) with relatively large SI values for compound 4.4 
(SI3T3= 100, SIEct1=167). Based on these data, the tetramic-acid compounds exhibited 
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many promising characteristics that suggested the potential for further development as 
inhibitors of T. vaginalis. 
	  
	  
Figure 4.10. Effect of lead compounds from different classed and metronidazole on the 
growth of Lactobacillus acidophilus grown in an anaerobic atmosphere for 18hr. the 
tetramic acid beauversetin has no off-target effects, like metronidazole.  
	  
	  
4.3 Conclusion and Future Directions 
A rapid and sensitive assay for T. vaginalis was developed and used to screen a 
variety of substances varying from pure compounds to complex fungal extracts. In 
screening a portion of our library of fungal extracts, we were able to isolate and identify 
pure compounds showing selective activity in T. vaginalis when counterscreened in 
Ect1/E6E7 human cells. One promising class of compounds, the tetramic acid derivatives, 
performed favorably in both of these counterscreens, suggesting that they possess real 
selectivity in the inhibition of T. vaginalis. Compound 4.4 emerged as a rather promising 
metabolite based on its potent activity against the parasite (EC50 = 0.060 µM) and limited 
toxicity against both the human Ect1/E6E7 cervical cell line (SI = 167) and L. 
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acidophilus (EC50 >0.060 µM). Although our testing was limited to 9 tetramic-acid-
containing natural products, the data suggested that modifications to the C-3 group of the 
trans-decaline system may provide additional opportunities for generating new analogues 
that have even further increased potency and selectivity. Further tests are now underway 
to test the tetramic-acid containing compounds as therapeutic agents against T. vaginalis 
infections. 
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4.4 Materials and Methods 
4.4.1 General Experimental 
 Optical rotation measurements were made on an AUTOPOL® III automatic polarimeter. 
The LC-ESIMS analyses were performed on a Shimadzu UFLC system with a quadrupole mass 
spectrometer using a Phenomenex Kinetex C18 column (3.0 mm × 75 mm, 2.6 µm) and MeCN-
H2O (0.1% HCOOH) gradient solvent system. HRESIMS spectra were measured using an 
Agilent 6538 Ultra High Definition (UHD) Accurate-Mass Q-TOF system. NMR spectra were 
obtained on Varian spectrometers (400MHz, 500 MHz for 1H and100, 125 MHz for 13C) using 
DMSO-d6 (Aldrich) as solvents. HPLC was performed on a Waters System equipped with a 1525 
binary HPLC pump coupled to a 2998 PDA detector with a Phenomenex C18 column (21.2 × 250 
mm or 10 × 250 mm, 5 µm particle size). 
 
4.4.2 Culture of Organisms 
Trichomonas vaginalis Donne (PRA-98) was purchased from the American Type Culture 
Collection (ATCC, Bethesda, MD).  The superior medium for growth of the organism was found 
to be Keister’s Modified TYI-S33 medium183 with the pH adjusted to 6.0, the pH optimum for 
growth of Trichomonas.  The medium was filter sterilized and aliquots stored frozen for future 
use.  Medium preparation was found to be very particular with regard to ingredients, most 
especially with the bovine bile component, which was only successful when Sigma B8381 was 
used, as opposed to other bovine bile products.  All assays mentioned in this publication were 
performed in this medium.  Trichomonads were grown in a 37°C incubator in sealed screw cap 
tubes for propagation and in an air incubator (21% O2, 0.04% CO2), candle jar (10% O2, 5% 
CO2), or with BD GasPak EZ Campy (6-16% O2, 2-10% CO2) or EZ Anaerobe sachets (<1% 
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O2, >13% CO2) for 96-well plate assays, in order to reduce oxygen levels and add carbon dioxide, 
a stimulator of Trichomonas growth.184 
NIH/3T3 (CRL-1658) mouse fibroblast and Ect1/E6E7 (CRL-2614) normal human 
ectocervical cell lines were purchased from ATCC.  NIH/3T3 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium with 5% FetalClone III (Hyclone) and Ect1/E6E7 cells in 
keratinocyte-serum free medium (K-SFM, GIBCO-BRL 17005-042) or RPMI 1640 medium 
with 5% FetalClone III and supplemented with EGF (10 ng/mL Novoprotein #C029). 
Lactobacillus acidophilus (ATCC 4356) was purchased from ATCC and grown on MRS 
agar and broth at 37°C under anaerobic condtions provided by BD GasPak EZ Anaerobe sachets. 
 
4.4.3 Trichomonas Assay 
A 250 µL cryopreserved (5% DMSO in liquid N2) aliquot of Trichomonas was thawed 
rapidly at 37 deg. C and put into a screw cap tube containing 12 mL of pre-warmed Modified 
TYI-S33 medium.  The sample was incubated for 24 hours at which point robust growth 
occurred and live trophozoites were counted.  A typical count yielded >30X106 cells per tube.  
Stock cultures were diluted into fresh medium to achieve 40,000 trophozoites per 100 µL of 
medium in each well of a 96-well plate.  Into each well, a pin tool or pipet tip was used to 
dispense extracts or pure compounds dissolved in dimethyl sulfoxide (DMSO).  Care was taken 
throughout to maintain the anaerobic nature of the medium and rapidity was observed (ideally 30 
minutes or less time exposed to normal atmospheric conditions).  Trichomonads tolerated a 
DMSO concentration of at least 1%.  DMSO and 25 µM metronidazole negative and positive 
controls were included.  The plates were placed in a humidified candle jar, the candle was lit, and 
the jar was sealed and placed in a 37 degrees’ Celsius incubator overnight for a 17-hour 
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incubation for the candle jar condition.  BD GasPak instructions were followed for that condition 
and plates incubated in either the provided pouch or the BD Anaerobe Container System.  After 
17 hours, the plates were removed and 100 µL per well of room temperature Trichomonas and 
Giardia assay and fixation (TGAF) solution was added per well.  TGAF solution is a PBS based 
solution we developed that contains 1% glutaraldehyde, 5 uM propidium iodide, and 5 uM 
acridine orange (HCl salt).  This solution was found to be stable for many months kept at room 
temperature and even longer when kept refrigerated.  The plates were shaken in a plate reader for 
thirty seconds to disperse any clumps and placed in the incubator for three hours for staining and 
fixation to occur.  The plates were then quantitatively imaged using the Perkin Elmer Operetta 
and the Harmony 3.5.1 software package.  Quantification involved the software identifying all 
trophozoites and subtracting live (green only) from dead (green and red) using a propidium 
iodide threshold of less than 6500 units; this threshold was determined to enable the assessment 
of membrane integrity and thus live/dead determination. 
For comparison, a traditional resazurin based assay using the plate reader was also 
performed.167 Known amounts of trichomonads were added to each well and then 10 µL of a 0.1 
mg/mL resazurin stock in PBS was added to each well and incubated for one hour at room 
temperature in the dark.  At 1 hr, plates were shaken and read on a fluorescence plate reader 
(Tecan Infinite M200) with a 556 nm excitation wavelength and an emission of 590 nm. 
 
4.4.4 Mammalian Cell Cytotoxicity Assay 
Mammalian cell assays were performed as described previously185 and viability 
determined by MTT assay186 or by a Calcein AM and Hoechst 33342 live cell area assay on the 
Operetta.  This assay was performed by adding 5 µL to each well of a 1:5 dilution in PBS of a 40 
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uM calcein AM and 160 uM Hoechst 33342 DMSO stock, incubating the plate for 30 minutes 
and reading the plate on the Operetta.  Harmony software was used to calculate the live cell area 
by finding all Hoechst-labeled nuclei and assigns live or dead assessments to each cell based on a 
threshold of green fluorescence.  Live cells are those with esterases still capable of cleaving the 
AM group from calcein AM, and glow bright green. 
 
4.4.5 Lactobacillus Acidophilus Viability Assays 
A colony of L. acidophilus was taken to 10 mL of MRS broth and vortexed. 100 µL was 
added to wells of a 96-well plate.  Test compounds in DMSO (0.05% final concentration DMSO) 
were added to the wells.  The plate was read on a microplate reader at 600 nm to establish a 
baseline value and the plate incubated overnight in a 37 deg. C incubator.  After 18 hours, the 
plate was read again and the baseline value subtracted to generate a change in optical density 
value. 
 
4.4.6 Tetramic Acid Producing Fungal Strains and Fermentation 
Five fungal isolates coded Miller-1 Cz-3, Miller-26 SEA-3, KY6863 TV8-3, Column L5 
SEA-1, CA9310 TV8-3, and were identified as Fusarium sp. isolate B, Fusarium sp. isolate C, 
Penicillium sp., Alternaria sp., and Phoma sp. respectively based on their ribosomal internal 
transcribed spacer (ITS) sequence data (GenBank accession numbers MK401898, MK401899, 
MK401895, MK401896, and MK401897, respectively). Fungal strain Miller-1 Cz-3, Miller-26 
SEA-3, KY6863 TV8-3 and CA9310 TV8-3, were fermented on a solid-state medium composed 
of Cheerios breakfast cereal supplemented with 0.3% sucrose solution for four weeks at room 
temperature (25°C). Fungal isolate Column L5 SEA-1 was inoculated into 16 L of PDB media 
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(10 g/L dried mashed potato, 5g/L glucose) supplemented with 2 g/L NaNO3 and cultured for 9 
days on a shaker. 
4.4.7 Purification of Tetramic Acid Derivatives 
The fungal cultures of Miller-1 Cz-3 were homogenized and extracted three times with 
EtOAc. The resulting EtOAc extract (25.0 g) was subjected to silica gel vacuum column 
chromatography (VLC) with elution steps of 1:1 hexane/DCM, DCM, 10:1 DCM/MeOH, and 
MeOH, yielding four fractions. The 10:1 DCM/MeOH fraction was subjected to HP20SS VLC 
and eluted with a step gradient of MeOH in water (30%, 50%, 70%, 90% and 100%), yielding 
five fractions. The 90% MeOH fraction from HP20SS VLC was further fractionated by 
preparative C18 HPLC (250 mm x 21.2 mm, 5 µm) with a MeCN-H2O gradient containing 0.1% 
HCOOH (70:30 to 100:0) to yield compounds 4.1 (56 mg) and 4.2 (18.9 mg). 
The fungal cultures of Miller-26 SEA-3 were homogenized and extracted three times 
with EtOAc. The resuting EtOAc extract (14.0 g) was subjected to silica gel VLC with elution 
steps of 1:1 hexane/DCM, DCM, 10:1 DCM/MeOH, and MeOH, yielding four fractions. The 
10:1 DCM/MeOH fraction was subjected to HP20SS VLC and eluted with a step gradient of 
MeOH in water (30%, 50%, 70%, 90%, 100%), yielding five fractions. The 70% MeOH fraction 
from HP20SS VLC was further fractionated by isocratic preparative C18 HPLC (250 mm x 21.2 
mm, 5 µm) with MeOH-H2O (75:25) to yield compound 4.3 (50 mg).  
The fungal cultures of KY6863 TV8-3 were homogenized and extracted three times with 
EtOAc. The resulting EtOAc extract (31.0 g) was subjected to silica gel VLC with elution steps 
of 1:1 hexane/DCM, DCM, 10:1 DCM/MeOH, and MeOH, yielding four fractions. The 10:1 
DCM/MeOH fraction was subjected to HP20SS VLC and eluted with a step gradient of MeOH 
in water (30%, 50%, 70%, 90%, 100%), yielding five fractions. The 90% MeOH fraction from 
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HP20SS VLC was further fractionated by preparative C18 HPLC (250 mm x 21.2 mm, 5 µm) 
with a MeOH-H2O gradient containing 0.1% HCOOH (85:15 to 100:0) to yield compounds 4.4 
(50 mg) and 4.5 (15mg). 
epipyrrolocin A (4.5): pale yellow plate; [α]20D 238 (c 0.1, MeOH); UV (MeOH) λmax (log 
ε) 238 (2.37), 265 (0.42), 295 (0.77); CD (MeOH) λmax (Δε) 234 (8.1), 291 (6.1); 1H and 13C 
NMR data, see Tables 2 and 3; HRESIMS m/z 456.2747 [M-H]- (calcd for 456.2747). 
Fungal culture broth of Column L5 SEA-1 was partitioned three times with EtOAc to 
obtain 3.0 g of organic residue. The organic residue was subjected to HP20SS VLC and eluted 
with a step gradient of MeOG in water (30%, 50%, 70%, 90%, 100%), yielding five fractions. 
The 90% MeOH fraction was further separated by preparative C18 HPLC (250 mm x 21.2 mm, 5 
µm) with a MeOH-H2O gradient containing 0.1% HCOOH (90:10 to 100:0), yielding a total of 
six fractions (Fr. 1-6). Fractions 2 and 4 were further purified by isocratic semi-preparative C18 
HPLC (250 mm x 10 mm, 5 µm) with MeCN-H2O containing 0.1% HCOOH (80:20) to yield 
compounds 4.6 (67mg) and 4.7 (7.5mg). 
epibeauversetin (4.7): pale yellow plate; [α]20D 409 (c 0.17, MeOH); UV (MeOH) λmax 
(log ε) 236 (4.39), 287 (4.11); CD (MeOH) λmax (Δε) 232 (8.2), 285 (9.8); 1H and 13C NMR data, 
see Tables 2 and 3; HRESIMS m/z 398.2337, [M-H]¯ (calcd for C24H32NO4, 398.2337). 
The fungal cultures of CA9310 TV8-3 were homogenized and extracted three times with 
EtOAc. The resulting EtOAc extract (38.0 g) was subjected to silica gel VLC with elution steps 
of 1:1 hexane/DCM, DCM, 10:1 DCM/MeOH, and MeOH, yielding four fractions. The 10:1 
DCM/MeOH fraction was subjected to HP20SS VLC and eluted with a step gradient of MeOH 
in water (30%, 50%, 70%, 90%, 100%), yielding five fractions. The 70% MeOH fraction from 
HP20SS VLC was further fractionated by isocratic preparative C18 HPLC (250 mm x 21.2 mm, 5 
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µm) with MeOH-H2O containing 0.1% HCOOH (85:15) to yield compounds 4.8 (140 mg) and 
4.9 (4 mg).  
 
4.4.8 Preparation of MTPA Ester 
Compound 4.5 (0.5 mg) was dissolved in pyridine-d6 and transferred into clean NMR 
tubes. The (R)-α-methoxy-α-trifluoromethyl-phenylacetyl chloride [(R)-MTPA-Cl] (5µl) was 
added into sample under an N2 gas stream. After mixing, it was incubated at 40 ̊C in a water bath 
and monitored every 2 hours by 1H-NMR. 1H-NMR data of the (S)-MTPA ester derivative (500 
MHz, pyridine-d5): δH 6.38 (1H, m, H-14), 6.07 (1H, m, H-15), 5.90 (1H, m, H-16), 5.69 (1H, m, 
H-13), 3.87 (1H, m, H-12), 2.37 (1H, m, H-17), 2.10 (1H, m, H-17), 1.20 (3H, d, 6.5, CH3-19).138 
The same method was used to yield (R)-Mosher esters derivative using (S)-α-methoxy-α-
trifluoromethyl-phenylacetyl chloride [(S)-MTPA-Cl].  
1H-NMR data of the (R)-MTPA ester derivative (500 MHz, pyridine-d5): δH 6.39 (1H, m, 
H-14), 6.07 (1H, m, H-15), 5.92 (1H, m, H-16), 5.72 (1H, m, H-13), 3.94 (1H, m, H-12), 2.37 
(1H, m, H-17), 2.10 (1H, m, H-17), 1.19 (3H, d, 6.5, CH3-19). 
 
4.4.9 Cleavage of the Tetramic Acid Ring and Marfey’s Reaction 
Sample (20 mg) was dissolved in methanol (0.6 mL) followed by addition of 1 M 
NaOH (0.075 mL) and a NaOCl solution (available chlorine 10−15%, 0.35 mL). The mixture 
was stirred at room temperature for 8 h and then it was quenched by 1 M aqueous Na2SO2 (3 
mL). The mixture was neutralized by addition of 1 M HCl. After removal of the solvent, the 
residue was diluted with H2O, and then the resulting mixture was extracted with ethyl acetate. 
The organic layer was dried in vacuo. The residue was dissolved in 6 M HCl (500 µl) and then 
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heated at 110 ̊C overnight. The hydrolysate was dried under a stream of N2 and then treated with 
1 M NaHCO3 (40 µl) and 1% FDAA/acetone (200 µl) at 70 ̊C for 1 h. The reactants were 
neutralized with 1 M HCl (40 µl), and diluted with MeCN (400 µl) prior to LC-MS analysis. 
FDAA derivatives of L-Ser/N-Me-L-Ser and D-Ser/N-Me-D-Ser standards were prepared in a 
similar manner. Aqueous solutions of serine standards (50 mM, 50 µl) were reacted, neutralized, 
and diluted following the same procedure. 171-172 
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Chapter 5. Cholinesterase Inhibitory Arisugacins L-Q from a Penicillium sp. 
Isolate Obtained through a Citizen Science Initiative and their Activities in a 
Phenotype-Based Zebrafish  
This chapter was adapted from a manuscript which is currently being prepared for 
submission in 2019. The authors are Wentao Dai, Imelda T. Sandoval, Shengxin Cai, Kaylee A. 
Smith, Richard Glenn C. Delacruz, Kevin A. Boyd, Jessica J. Mills, David A. Jones and Robert 
H. Cichewicz. 
The work presented in this chapter was conducted as follows: Imelda T.Sandoval 
conducted the bioassay, Wentao Dai performed extraction, purifications and structure 
elucidation of compounds 5.1-5.14.  
	  
5.1 Introduction 
The cholinesterases are an important class of enzymes that catalyze the hydrolysis of 
ester bond linkages in choline-containing molecules. This group of enzymes is further 
subdivided into two major families: acetylcholinesterase (AChE) and butyrylcholinesterasse 
(BuChE) whose names reflect the enhanced rates at which these enzymes hydrolyze 
acetylcholine (ACh) and butyrylcholine, respectively.187 Biomedically, acetylcholinesterases 
play several important roles revolving around their abilities to rapidly hydrolyze ACh (a key 
neurotransmitter) and thus terminate nerve signal transmission. Consequently, the therapeutic 
inhibition of AChE using drugs such as donepezil, rivastigmine and galantamine is an effective 
clinical strategy for symptomatic relief in several types of pathologies including Alzheimer’s 
disease,81-82 Parkinson’s disease,83 myasthenia gravis,84 and glaucoma85. 
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In addition to the treatment of human diseases, AChE inhibitors have found widespread 
uses as insecticides (e.g., aldicarb, carbofuran), fungicides (e.g., butylate, pebulate) and 
herbicides (e.g., ferbam, mancozeb).187 Many types of plant-derived natural products have been 
identified as AChE inhibitors with additional reports emerging from fungi and marine source 
suggesting that nature is a valuable resource to mine for AChE inhibitor scaffolds.188-194 Among 
the handful of reported fungus-derived natural products that disrupt AChE activity, the territrems, 
arisugacins, and terreulactones stand out as a structurally distinct group of meroterpenoids that 
exhibit potent and selective AChE inhibition. To date, 7 territrems,86-87, 93, 95 12 arisugacins,92, 97-
98, 101-102 and 6 terrulactones95, 103, 105 have been reported with the most potent inhibitors 
exhibiting IC50 values extending into the low nanomolar range.92, 104 
Zebrafish have been used as a model organism for phenotype-driven drug discovery since 
2000.195-196 As one of the few groups to investigate chemical libraries in an unbiased phenotype 
screen, we have shown from previous work that we can utilize zebrafish to assign mechanism of 
action, in juxtaposition with zebrafish genetics, to a class of compounds with unknown 
bioactivity.197 Zebrafish have several desirable characteristics that make them ideal as chemical 
testing platforms including high fecundity, small-size (amendable to use in microtiter plate 
formats), and transparent embryos that rapidly develop ex utero. This latter point is important 
because it allows for the visualization and scoring of diverse phenotypes, which can provide 
critical insights into the mechanistic effects of many chemicals. Compared to simpler cell-based 
assays, these complex phenotypic cues can help with the early-stage prioritization of hits and 
provide an additional tool for filtering through subtle, but meaningful differences in how 
molecules behave in intact organisms. Notably, zebrafish share a high degree of genetic and 
physiological similarity with humans; approximately 70% of human genes have an orthologue in 
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zebrafish, enabling drug screening in zebrafish to have direct therapeutic relevance to a host of 
human diseases.196, 198-204 
Given the immense number of mechanistically uncharacterized bioactive compounds 
produced by fungi, a collaborative effort was launched to assess a pilot-scale set of fungal natural 
product extracts as a resource for integrating into a zebrafish-focused bioactive compound 
discovery program. In the course of this study, an extract prepared from a Penicillium sp. isolate 
was found to induce a paralysis phenotype in zebrafish embryos, indicative of central nervous 
system (CNS) modulators,205 and it was prioritized for further investigation. Bioassay-guided 
investigation led to the identification of 14 meroterpenoids, including 6 previously undescribed 
natural products. The purification, structure determination, and biological characterization of the 
metabolites, including results from the zebrafish-based phenotype screen are described in this 
report. 
 
5.2 Results and Discussion 
5.2.1 Zebrafish-Based Phenotype Screen of Fungal Crude Extract 
Studies were performed using a circumscribed set of 384 fungal extracts prepared from 
fungi secured from the Great Lakes (MI, USA) and soil samples from Lawton (OK, USA) that 
were obtained through the Citizen Science Soil Collection Program operated out of the 
University of Oklahoma.131 Whereas a majority of the extracts had no effect on normal 
development,  46 samples (12%) resulted in a wide range of viable phenotypes that included 
growth arrest, head and tail defects, edema, and behavioral abnormalities (Figure 5.1). In 
addition, 45 crude extracts (12%) were lethal to the embryos (Figure 5.1). To examine this 
further, a dose curve analysis from 10 to 0.1 µg/ml was performed for 34 samples that caused 
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death, resulting in 16 extracts that gave specific developmental abnormalities at lower 
concentrations (Table C2). This demonstrates that embryonic lethality as an assay outcome 
should not be dismissed, as it can lead to viable phenotypic aberrations upon optimization of 
experimental conditions such as dosing and time of treatment. 
 
	  
Figure 5.1. Zebrafish phenotype screen reveals bioactive fungal samples. A. Distribution of 
assay outcomes from screening of fungal extracts. B. Examples of phenotypes observed include 
growth arrest (1-3), edema (black arrow), abnormal head (green arrow) and tail (blue arrow) 
development and undulated notochord (red arrow). 
 
5.2.2 Purification Natural Products from the Penicillium sp. Isolate 
Fungal extracts that affected motility were prioritized because of its clinical relevance, as 
this phenotype often indicates perturbation of the CNS.206 We chemically investigated an extract 
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derived from a Penicillium sp. isolate, which induced paralysis as shown by very limited 
movement of zebrafish embryos when stimulated externally with a tip, similar to phenotype 
resulting from exposure to azinphos-methyl (AZM), a known AChE inhibitor (Figure 5.2, Figure 
C1). Further purification of the crude extract, using paralysis as assay readout, revealed fungal 
metabolites belonging to the arisugacin family of compounds. 
 
	  
Figure 5.2. Zebrafish phenotype screen reveals fungal extracts that impaired motility. 
Morphological phenotype exhibited by crude extract and representative subfractions that 
impaired motility comparable to phenotype resulting from treatment with known AChE inhibitor, 
AZM  (1st, 3rd panels). DMSO served as negative control. Traces summarizing movement of 
zebrafish embryos (black dot) in response to external stimulus (represented by a blue line) are 
shown in panels 2 and 4.  
DMSO
AZM
crude extract 
subfraction 1
subfraction 2
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subfraction 4
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Figure 5.3. Structures of compounds 5.1-5.14. 
 
For chemical studies, the Penicillium sp. isolate was grown on Cheerios breakfast cereal 
and the resulting mycelial mass was extracted with EtOAc, affording a crude extract that was 
subjected to bioassay-guided fractionation. This resulted in the purification of metabolites 5.1-
5.3, which were identified as arisugacin D (5.1), arisugacin J (5.2), and arisugacin I (5.3) (Figure 
5.3) based on comparisons of their 1H NMR spectra, optical rotation values, and LC-ESIMS data 
to authentic samples and published data.101, 207 Both 5.1 and 5.3 have been reported as selective 
AChE inhibitors with IC50 values of 2.5 µM and 3.5 µM, respectively.207 This initial observation, 
combined with the impaired motility phenotype from our zebrafish screen, inspired us to further 
pursue the structure identification of the compounds contained within the bioactive extract 
because other related structures such as arisugacin A and B, as well as territrem A and B have 
shown rather high levels of selectivity for AChE with IC50 values ranging from 1 – 25.8 nM.208 
With LC-ESIMS evidence for the presence of several structurally related metabolites in the 
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Penicillium sp. extract including several compounds that could not be readily dereplicated, we 
decided that further investigation of the bioactive components present in this sample was 
warranted in the hope of securing additional potent bioactive congeners (Figure 5.3). 
 
	  
Figure 5.4. 1H-1H COSY (blue bold lines) and key HMBC (red arrows) correlations of 
compounds 5.4-5.5, 5.8, 5.12-5.14. 
 
Arisugacin L (5.4) was obtained as a white amorphous powder and its molecular formula 
was established as C27H34O8 based on HRESIMS data that featured ions at m/z 487.2341 [M+ 
H]+, and 509.2155 [M + Na]+. This corresponded to 11 units of unsaturation. An inspection of 
the 1H and 13C NMR data for 5.4 (Tables 5.1 and 5.2) revealed that this compound shared many 
structural features with known metabolite 5.2.101 Considering that 5.4 contained one additional 
oxygen atom, further inspection of the data revealed that C-19 in 5.4 was more deshielded (δC 
65.4) suggesting that it was attached to a hydroxy group. Analysis of the HMBC and COSY data 
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provided substantiation for the structure of the remaining portions of the molecule confirming 
that 5.4 was a new tetrahydroxy arisugacin (Figure 5.4). 
Turning to address the orientation of the stereogenic carbon atoms in 5.4, 1H-1H ROESY 
correlation data played a key role in establishing the metabolite’s relative configuration (Figure 
5.5). Two distinct sets of ROESY correlations were observed arising from the hydrogens 
occupying opposite faces of the molecule’s dodecahydro-1H-benzo[f]chromene core. 
Specifically, ROESY correlations among H3-26 ↔ H3-24, H3-25, and H-12 (δH 2.71); H3-25 ↔ 
H-16 (δH 1.94); and H3-24 ↔ H-21 provided evidence that those atoms were located on one face 
of molecule. A second set of ROESY correlations among H2-12 (δH 3.14) ↔ H-19 and OH-13, 
as well as between H3-23 ↔ OH-17, H-21, and H-16 (δH 1.73) indicated those atoms occupied 
the opposite face of the molecule. This left one hydrogen atom, H-21, whose relative orientation 
remained ambiguous; however, an examination of its splitting pattern (double doublet) and 
coupling constant data (J = 2.3 and 2.8 Hz), indicated this hydrogen occupied an equatorial 
position. Taking these data into consideration, the relative configuration of 5.4 was assigned to 
be 13S*,14R*,17R*,18S*,19R*,21R*, which is similar to several known arisugacin analogues 
containing three trans-fused six-member ring systems.101, 104, 207 Using a modified Mosher 
esterification strategy, C-21 was determined to have an R configuration (Figure 5.6), thus, the 
absolute configuration of 5.4 was determined to be 13S,14R,17R,18S,19R,21R. 
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Figure 5.5. 3D molecular models of compounds 5.4-5.5, 5.8, 5.12-5.13 showing key ROESY 
correlations (blue dashed arrows). 
 
Arisugacin M (5.5) was obtained as a white amorphous powder. The molecular formula 
was assigned as C27H34O7 based on its HRESIMS data ([M+H]+ ion at m/z 471.2393; [M+Na]+ 
ion at m/z 493.2210) indicating 11 units of unsaturation. An analysis of the 13C NMR and HSQC 
data revealed that the hydroxyl group observed on C-19 in 5.4 was missing in 5.5 and instead, a 
new methylene signal was present (δC 26.2). This conclusion was supported by an analysis of the 
HMBC and COSY data, which also confirmed the proposed bond-line structure of 5.5 (Figure 
5.4). 
1H-1H ROESY correlation data were instrumental for solving the relative configuration of 
5.5 (Figure 5.4). Once again, two sets of correlations emerged based on which face of the 
dodecahydro-1H-benzo[f]chromene scaffold that the hydrogen atoms occupied. The first series 
of observed correlations included H3-26 ↔ H3-25, H3-24, and H-19 (δH 1.11), as well as between 
H3-25 ↔ H-16 (δH 1.87). On the opposite face of 5.5, ROESY correlations were observed 
between H-19 (δH 2.11) ↔ OH-13, H-21, and OH-17, as well as H3-23 ↔ H-16 (δH 1.61). These 
data pointed toward a 13S*,14R*,17R*,18S*,21S* relative configuration. The absolute 
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configuration of C-21 was next determined to be S by modified Mosher’s method (Figure 5.6), 
thus the overall absolute configuration of 5.5 was assigned as 13S, 14R, 17R, 18S, and 21S. 
 
	  
Figure 5.6. ΔδS-R values obtained in pyridine-d5 of the MTPA ester of compounds 5.4, 5.5, and 
5.12. 
 
Arisugacin N (5.8) was obtained as a white amorphous powder. The molecular formula 
was established to be C27H32O8, on the basis of the HRESIMS data ([M+ H]+ ion at m/z 485.2165; 
[M + Na]+ ion at m/z 507.1982). The 1H and 13C NMR data for 5.8 showed substantial 
similarities to 5.4 except for a new carbonyl signal (δC 212.8) representing a ketone that appeared 
in place of a hydroxymethine (C-21 in 5.4). Analysis of the 1H-1H COSY and HMBC correlation 
data provided confirmation that other than the noted change in C-21, the atom-bond 
arrangements in 5.8 were the same as those observed for 5.4 (Figure 5.4). Next, 1H-1H ROESY 
data [H3-26 ↔ H3-24 and H3-25; H3-24 ↔ H-20 (δH 2.74); H3-25 ↔ H-12 (δH 2.65); H-19 ↔ H-
12 (δH 2.95), OH-13, OH-17, and H3-23; as well as H3-23 ↔ H-20 (δH 2.54)] were used to 
confirm a 13S*,14R*,17R*,18S*,19R* relative configuration for 5.8 (Figure 5.5). All attempts to 
create at C-19 Mosher ester derivative failed, which limited our ability to assign the absolute 
configuration for 5.8. However, in view of the consistent configurations observed for the C-13, 
C-14, C-17, and C-18 stereogenic centers in this metabolite series (5.1-5.7), as well as the similar 
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optical rotation values observed for these metabolites,101, 207 we propose that the absolute 
configuration for 5.8 is likely 13S,14R,17R,18S,19R. 
Arisugacin O (5.12) was obtained as a white amorphous powder. HRESIMS provided 
molecular ions ([M+ H]+, [M + Na]+ at m/z 485.2164 and 507.1989, respectively) indicative of 
the molecular formula C27H32O8. This molecular formula was the same as that for 5.8 and 
comparisons of their 1H and 13C NMR data (Table 5.1 and 5.2) indicated that the structures of 5.8 
and 5.12 were highly similar. A comparative analysis of the HMBC data for 5.8 and 5.12 
revealed that the C-19 hydroxymethine in 5.8 was oxidized to a ketone in 5.12 [H3-26 (δH 1.24) 
→  C-19 (δC 209.6)], while the C-21 ketone in 5.8 now appeared in a reduced state as a 
hydroxymethine in 5.12 [H3-23 (δH 0.96) →  C-21 (δC 72.4)] (Figure 5.4). The relative 
configuration of 5.12 was determined to be 13S*,14R*,17R*,18S*,21R* based on an analysis of 
1H-1H ROESY correlation data (Figure 5.5). Specifically, ROESY correlations among protons 
H3-26 ↔ H3-25, H3-24, and H-21; H3-25 ↔ H-15 (δH 1.60) and H-12 (δH 2.72); H3-24 ↔ H-21; 
H-12 (δH 3.39) ↔ OH-13; as well as H-15 (δH 2.22) ↔ OH-17 supported a 
13S*,14R*,17R*,18S*,21R* relative configuration. The absolute configuration of C-21 was 
determined to be R by the modified Mosher’s method (Figure 5.6) enabling us to assign the 
overall absolute configuration of 5.12 as 13S, 14R, 17R, 18S, 21R. 
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Table 5.1.1HNMR Data for Compounds 5.4, 5.5, 5.8, 5.12-5.14 (δ ppm) 
 
 
Arisugacin P (5.13) was obtained as a white amorphous powder and its molecular 
formula was determined to be C27H30O5 by the analysis of the HRESIMS data including an [M+ 
H]+ ion at m/z 435.2181 and an [M + Na]+ ion at m/z 435.2181 requiring 13 units of unsaturation. 
The HSQC data revealed that in comparison to compounds 5.8 and 5.12, metabolite 5.13 
possessed two new deshielded methine carbon atoms (δC 157.5 CH and 125.3 CH), which, based 
on 13C NMR (Table 5.2) and HMBC (Figure 5.4) data, were determined to be part of a α, β-
unsaturated carbonyl system associated with ketone C-21. Further investigation of the HMBC 
data revealed that 5.13 was structurally similar to the previously described meroterpenoid, 
terreulactone B,104 which had been isolated from an Aspergillus terreus. The major difference 
between these metabolites was that both the C-13 and C-17 hydroxy groups reported in 
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terreulactone B were missing and instead, metabolite 5.13 featured two new methine spins (δC 
45.8 and 52.1) (Table 5.2). The relative configuration of 5.13 was determined to be 
13S*,14R*,17R*,18S* based on 1H-1H ROESY correlation data (Figure 5.5). Specifically, 
correlations among protons H3-26 ↔ H-16 (δH 1.62), H3-24, and H3-25; H3-25 ↔ H-12 (δH 2.31); 
H3-23 ↔ H-17 and H-16 (δH 1.74); as well as H-12 (δH 2.67) ↔ H-13 were instrumental in the 
assignment of the molecule’s configuration. To evaluate the absolute configuration of 5.13, the 
experimental and calculated ECD spectra of 5.13 were compared (Figure 5.7). The calculated 
ECD spectrum displayed Cotton effect that were similar to the experimentally-derived ECD 
spectrum, supporting a 13S,14R,17R,18S absolute configuration for compound 5.13. 
 
	  
Figure 5.7. Comparison of the experimental and calculated ECD spectra of 5.13. 
 
Arisugacin Q (5.14) was obtained as a white amorphous powder. HRESIMS analysis 
provided both [M+ H]+ (m/z 423.2517) and [M + Na]+ (m/z  445.2341) ions that supported a 
molecular formula of C27H34O4, requiring 11 units of unsaturation. The 1H, 13C and HSQC NMR 
experiments (Tables 5.1 and 5.2) provided data for a molecule that largely mirrored compound 
5.3,101 which was the first arisugacin reported to possess a largely linear sesquiterpenoid moiety. 
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Notable differences in 5.14 compared to 5.3 were the presence of carbon spins attributable to an 
additional olefinic bond (δc 125.4, 131.7) in 5.14, which coincided with the loss of two oxygen 
atoms. The 1H-1H COSY correlation data revealed couplings between the H2-20 (δH 2.04) and H-
21 (δH 5.06), while HMBC correlations from H-20 → C-22, H3-23 →C-21, and H3-24 → C-21, 
secured the structural assignment for the new portion of the compound. Further investigation 
using the 2D NMR data (Figure 5.4) helped establish the complete structure of 5.14 (Figure 5.3). 
The geometry of the two double bonds (∆13 and ∆17) were determined as E,E on the basis of 
ROESY correlations among H2-12 ↔ H3-26, H-13 ↔ H2-15, H2-16 ↔ H3-25, and H-17 ↔ H2-
19 (Figure 5.8). 
 
	  
Figure 5.8. 3D molecular models of compound 5.14 showing key ROESY correlations (blue 
dashed arrows). 
 
In addition to the new compounds, several more metabolites were also observed and 
subsequently purified yielding the known compounds epi-arisugacin E (5.6),102 arisugacin F 
(5.7),207 arisugacin C (5.9),98 arisugacin G (5.10),207 and terreulactone C (5.11).104 The structures 
of these compounds were determined based on comparisons of 1H and 13C NMR and HRESIMS 
data with previously reported data. 
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Table 5.2. 13C NMR Data for Compounds 5.4, 5.5, 5.8, 5.12-5.14 (100 MHz, δ ppm) 
 
No. 
δC, mult 
4b 5c 8d 12d 13d 14b 
1 127.6 CH 127.2 CH 126.8 CH 126.8 CH 127.0 CH 127.8 CH 
2 115.1 CH 114.2 CH 114.5 CH 114.5 CH 114.5 CH 115.3 CH 
3 162.4 C 161.8 C 161.1 C 161.0 C 161.2 C 162.4 C 
4 115.1 CH 114.2 CH 114.5 CH 114.5 CH 114.5 CH 115.3 CH 
5 127.6 CH 127.2 CH 126.8 CH 126.8 CH 127.0 CH 127.8 CH 
6 125.4 C 123.6 C 123.6 C 123.6 C 123.4 C 125.7 C 
7 158.2 C 158.7 C 157.0 C 157.0 C 157.6 C 158.4 C 
8   97.4 CH   96.6 CH   96.6 CH   96.6 CH   96.5 CH   98.4 CH 
9 163.4 C 164.1 C 162.4 C 162.4 C 163.1 C 167.5 C 
10   99.6 C   96.7 C   97.4 C   97.3 C   97.8 C 102.9 C 
11 164.4 C 165.6 C 163.4 C 163.3 C 162.9 C 165.5 C 
12   29.9 CH2    25.7 CH2   27.4 CH2   26.7 CH2   16.8 CH2   23.3 CH2 
13   77.9 C   77.6 C   76.3 C   75.6 C   45.8 CH 123.4 CH 
14   82.4 C   82.2 C   81.4 C   80.8 C   80.5 C 135.4 C 
15   29.9 CH2   29.5 CH2   28.5 CH2   28.4 CH2   39.2 CH2   40.7 CH2 
16   26.5 CH2   26.0 CH2   25.3 CH2   25.4 CH2   19.3 CH2   27.4 CH2 
17   84.7 C   80.1 C   80.7 C   81.5 C   52.1 CH 125.2 CH 
18   49.1 C   43.6 C   47.9 C   57.1 C   39.0 C 135.6 C 
19   65.4 CH   26.0 CH2   67.1 CH 209.6 C 157.5 CH   40.6 CH2 
20   37.2 CH2   27.3 CH2   44.7 CH2   45.8 CH2 125.3 CH   27.6 CH2 
21   78.9 CH   73.7 CH 212.8 C   72.4 CH 203.5 C 125.4 CH 
22   42.2 C   44.5 C   52.8 C   42.9 C   44.0 C 131.7 C 
23   23.8 CH3   22.8 CH3   23.3 CH3   20.7 CH3   27.3 CH3   26.0 CH3 
24   24.7 CH3   18.7 CH3   21.7 CH3   25.5 CH3   21.4 CH3   17.9 CH3 
25   24.8 CH3   24.6 CH3   23.4 CH3   23.5 CH3   20.7 CH3   16.6 CH3 
26   17.4 CH3   21.0 CH3   16.0, CH3   18.6 CH3   18.1 CH3   16.3 CH3 
27   55.8 CH3   55.6 CH3   55.4, CH3   55.4 CH3   55.5 CH3   56.0 CH3 
aMultiplicities were assigned based on 1H, 13C and HSQC NMR (13C 100/1H 500 MHz) 
experiments. bObserved in acetone-d6. cObserved in CDCl3. d Observed in DMSO-d6. 
 
5.2.3 Testing of Natural Products from the Penicillium sp. Isolate 
Following the purification of these compounds, all metabolites were evaluated in 
zebrafish embryos. New compounds 5.5 and 5.12-5.14 induced paralysis with compound 5.12 
being the most active at a test concentration of 1 µM (Table 5.3). Additionally, embryos exposed 
to compound 5.12 exhibited defects in myotome structure as shown by in situ hybridization for 
xirp2a, closely phenocopying embryos treated with the known AChE inhibitors, azinphosmethyl 
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(APM) and physostigmine (Figure 5.9A and B).187, 209 This is consistent with previous reports of 
AChE inhibition leading to severe abnormalities in muscle development.206 Treatment with the 
known BuChE inhibitor, tetraisopropyl-pyrophosphoramide (iso-OMPA), did not result in 
compromised motility or aberrant myotome development (Figure 5.9A and B).210 Using an in 
vitro assay to investigate whether the new arisugacins directly inhibit AChE, we found that 
compounds 5.5 and 5.12 showed the strongest inhibition, with IC50 values of 3.9 and 0.19 µM, 
respectively (Table 5.3 and Figure 5.9C). Compounds 5.4 and 5.8 did not impair motility in 
zebrafish embryos; however, these compounds did inhibit in vitro AChE activity, which suggests 
that certain pharmacological parameters were not met to cause bioactivity in vivo (Table 5.3).  
 
	  
Figure 5.9. Novel arisugacin compounds show acetylcholinesterase inhibitory activity. A. 
Phenotypes of 72 hpf embryos that exhibited impaired motility with early compound treatment. 
B. In situ hybridization for myotome marker, xirp2a (xin actin binding repeat containing 2a), in 
72 hpf embryos. Boxed figure is enlargement of the trunk to emphasize abnormalities in 
myotome (black arrow) structure. C. IC50 of new arisugacin analogs were obtained in an in vitro 
AChE inhibition assay. 
The known compounds 5.1, 5.3, 5.9-5.10 produced a paralysis phenotype in zebrafish 
with compound 5.3 and 5.10 causing myotome structural abnormalities, as well as demonstrating 
the abilities to inhibit AChE in vitro (Figure 5.10, Table 5.3). Both compounds have not been 
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shown to be biologically active but possess weak AChE inhibitory properties in previous in vitro 
assays.101, 207 Compound 5.11, which has been previously reported to be potent and selective 
AChE inhibitor did not induce phenotypic changes in the zebrafish (Table 5.3).104 All 
compounds showed minimal inhibition of BuChE, however, only compound 5.12 stood out as 
highly selective towards AChE (Table 5.3). 
 
	  
Figure 5.10. Bioactivity of known arisugacin compounds with no previously reported AChE 
bioactivity. A. Phenotypes of 72 hpf embryos that exhibited impaired motility with early 
compound treatment. B. In situ hybridization for xirp2a in 72 hpf embryos. Boxed figure is 
enlargement of the trunk to emphasize abnormalities in myotome (black arrow) structure. C. IC50 
of arisugacins C, G and I were obtained in an in vitro AChE inhibition assay. 
 
There were several compounds that had consistent bioactivity in both phenotype-based 
zebrafish screen and in vitro AChE inhibition assay (Table 5.3). However, there were samples 
that showed opposite results, for example, compound 5.11 did not affect motility in zebrafish 
while physostigmine induced phenotype only at 100 µM. Both compounds inhibited AChE in 
vitro at low nanomolar concentrations, which indicates that there are pharmacological properties 
that need to be addressed for these compounds to be useful as potential therapeutics. AZM, in 
contrast, caused paralysis in zebrafish embryos at 1 µM but showed weak inhibition of AChE in 
vitro. This is consistent with the mechanism of toxicity of AZM, its conversion to the oxon form 
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by cytochrome P450 has been found to be responsible for its AChE inhibitory activity, which is 
not readily apparent in an in vitro assay. Lastly, we have observed bioactivity for compounds 5.3 
and 5.10 in developing zebrafish embryos, both of which were weakly active in in vitro assays. 
These examples illustrate the unique advantage of using a whole organism-based phenotype 
screen such as the zebrafish, as it not only provides information about biological activity of small 
molecules in vivo, but insights about their pharmacokinetic and pharmacodynamic characteristics 
as well. This knowledge is critical in determining and prioritizing lead compounds, and in 
facilitating drug discovery efforts in general. 
 
5.3 Conclusion and Future Directions 
Our findings demonstrate the utility of the zebrafish in rapidly deconvoluting complex 
mixtures into its active components and elucidating their mechanism of action. From 384 fungal 
extracts, six new and eight known meroterpenoids were purified from a Penicillium sp. isolate. 
Four of the new compounds (5.5, 5.12-5.14) induced paralysis in zebrafish with compound 5.12 
demonstrating potent and selective AChE inhibitory activity under both in vivo and in vitro 
conditions. AChE inhibitors have found clinical use for treating various human malignancies that 
include bladder distention, glaucoma, vascular dementia and symptoms of Alzheimer’s Disease 
(AD). Currently, majority of drugs approved for AD treatment are AChE inhibitors, but the need 
to develop better therapeutics to address cognitive impairment remains.211 Our discovery of new 
arisugacin compounds, some with potent and specific AChE inhibitory activity, would enable 
further structure-function analyses that could lead to the development of better AChE inhibitors 
in the clinic.  
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Table 5.3. Bioactivity of compounds 5.1-5.14. 
Compound 
Zebrafish Assay 
Active 
Concentrationa 
(µM) 
 
AChE Inhibitionb 
at 50 µM 
 (%) 
 
BuChE Inhibitionb  
at 50 µM 
(%) 
 
AChE 
inhibition 
IC50 (µM) 
 
Iso-OMPAc - 1.3 15.1 >100 
APMd 1  12.2 3.3 nt 
Physostigmined 100  99.8 93.2 0.0078 
5.1 10  60.1 4.7 nt 
5.2 - 83.4 0 nt 
5.3 10  34.1 4.7 >100 
5.4 - 29.2 0 >100 
5.5 50  89.4 4.7 3.9 
5.6 - 75.4 7.0 nt 
5.7 - 3.0 4.7 nt 
5.8 - 83.6 0 4.6 
5.9 5  95.1 32.6 1.4 
5.10 5  26.9 11.6 >100 
5.11 - 96.6 9.3 nt 
5.12 1  98.0 0 0.191 
5.13 5  40.3 0 66 
5.14 50  4.3 0 >100 
 
a Active concentration refers to the lowest compound concentration where it induced 
paralysis in zebrafish embryos treated at 7 hpf and evaluated for phenotype at 72 hpf.  
A dash (-) signifies no bioactivity in vivo at 100 µM or lower. 
b Inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase  
(BuChE) was determined at sample concentration of 50 µM.  
c BuChE inhibitor. d AChE inhibitor. nt-not tested. 
Iso-OMPA, APM stand for tetraisopropylpyrophosphramide and azinphosmethyl 
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5.4 Materials and Method 
5.4.1 General Experimental 
Optical rotations were measures on a Rudolph Research Autopol® III. NMR data were 
obtained on Varian VNMR spectrometers (500 MHz and 600MHz for 1H and 2D NMR, 100 
MHz for 13C). The LC-ESIMS analyses were performed on a Shimadzu UFLC system with a 
quadrupole mass spectrometer using a Phenomenex Kinetex C18 column (3.0 mm × 75 mm, 2.6 
µm) and MeCN-H2O (0.1% HCOOH) gradient solvent system. Accurate mass data was collected 
on an Agilent 6538 high-mass-resolution QTOF mass spectrometer. Analytical and Semi-
preparative HPLC were performed on a Waters 2998 photodiode array detector, the column used 
were Phenomenex Gemini 5 µm C18 column (110Å, 250*4.6 mm, 1 mL/min; 110Å, 250*10 
mm, 4 mL/min), Kinetex 5 µm Biphenyl (110Å, 250*4.6mm, 1 mL/min; 110Å, 250*10mm, 4 
mL/min). All solvents are of ACS grade or better. 
 
5.4.2 Fungal Strain and Fermentation 
The fungal isolate was obtained from a soil sample submitted by a citizen scientist from 
Lawton, Oklahoma to the University of Oklahoma Citizen Science Soil Collection Program. The 
isolate was identified as a probable Penicillium sp. (most closely associate to Penicillium 
oxalicum) based on analysis of its ribosomal internal transcribed spacer (ITS) sequence data 
(GenBank accession number MK722362) by comparison to the BLAST database. Fermentation 
was performed by inoculating fungal mycelia and spores on to a solid-state medium composed of 
Cheerios® breakfast cereal supplemented with a 0.3% sucrose solution. The fungus was grown 
for four weeks at room temperature (25°C). 
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5.4.3 Extraction and Isolation 
The fungal biomass was extracted with EtOAc (´3) and the organic solvent was 
concentrated under vacuum to generate the crude extract (130 g). The crude extract was 
separated into five fractions (Fr.1-Fr.5) by silica gel vacuum liquid chromatography [eluted with 
equal volumes of hexane-CH2Cl2 (1:1), CH2Cl2, CH2Cl2-MeOH (10:1, 1:1)] and MeOH. Fr.3 
(eluted with 10:1 CH2Cl2-MeOH) was subjected to HP20ss vacuum liquid chromatography 
(eluted with 30%, 50%, 70%, 90%, 100% MeOH in H2O) to yield five subfractions. The fourth 
fraction was found active zebrafish assay and it was further separated by semi-preparative HPLC 
(eluted with 40:60 ACN:H2O, with 0.1% formic acid in H2O) yielded compounds 5.1 (1.9 mg), 
5.2 (3.7 mg), 5.3 (1.5 mg) 5.4 (4.5 mg), 5.5 (7.9 mg), and 5.6 (2.6 mg). Subfraction 5 (100% 
MeOH) was further purified by semi-preparative HPLC (70:30 ACN:H2O with 0.1% HCOOH) 
to afford compounds 5.7 (2.2 mg), 5.8 (3.7 mg), 5.9 (7.9 mg), 5.10 (10.1 mg), 5.11 (4.0 mg), 
5.12 (2.2 mg), 5.13 (1.1 mg), and 5.14 (2.1 mg). 
Arisugacin M (5.4): amorphous, white powder; [𝔞]20D  + 69.3 (c, 0.225, MeOH); 1H and 13C 
NMR, see Table 1 and Table 2; HRESIMS [M+H]+ m/z 487.2341, [M+Na]+) m/z 509.2155 
(calcd for C27H35O8, 487.2326,  C27H34O8Na, 509.2146). 
Arisugacin N (5.5): amorphous, white powder; [𝔞]20D  +64.8 (c, 0.395, MeOH); 1H and 13C 
NMR, see Table 1 and Table 2; HRESIMS [M+H]+ m/z 471.2393, [M+Na]+) m/z 493.2210 
(calcd for C27H35O7, 471.2377  C27H34O7Na, 493.2197). 
Arisugacin O (5.8): amorphous, white powder; [𝔞]20D  + 64.9 (c, 0.185, MeOH); 1H and 13C 
NMR, see Table 1 and Table 2; HRESIMS [M+ H]+ m/z 485.2165, [M + Na]+) m/z 507.1982 
(calcd for C27H33O8, 485.2170,  C27H32O8Na, 507.1989). 
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Arisugacin L (5.12): amorphous, white powder; [𝔞]20D  + 4.5 (c, 0.11, MeOH); 1H and 13C NMR, 
see Table 1 and Table 2; HRESIMS [M+H]+ m/z 485.2164, [M+Na]+) m/z 507.1989 (calcd for 
C27H33O8, 485.2170,  C27H32O8Na, 507.1989). 
Arisugacin P (5.13): amorphous, white powder; [𝔞]20D  + 100 (c, 0.05, MeOH); 1H and 13C 
NMR, see Table 1 and Table 2; HRESIMS [M+ H]+ m/z 435.2181, [M + Na]+) m/z 457.1993 
(calcd for C27H31O5, 435.2166,  C27H30O5Na, 457.2064). 
Arisugacin Q (5.14): amorphous, white powder; 1H and 13C NMR, see Table 1 and Table 2; 
HRESIMS [M+ H]+ m/z 423.2517, [M + Na]+) m/z 445.2341 (calcd for C27H35O4, 423.2530,  
C27H34O4Na, 445.2349). 
 
5.4.4 Preparation of MTPA Esters 
Compound 5.4, 5.5 and 5.12 (0.2 mg each) were dissolved separately in pyridine (500 µL) 
and transferred into NMR tubes. 2 µL of (S)-𝔞-methoxy-𝔞-trifluoromethylphenylacetic acid 
(MTPA) was added to each sample and the reaction mixture monitored every 2 h by 1H-NMR. 
(S)-MTPA esters were prepared in a similar way using (R)-𝔞-methoxy-𝔞-
trifluoromethylphenylacetic acid. 
(R)-MTPA Ester of 5.4: 1H NMR (5 00MHz, pyridine-d5) δ 5.49 (H-21), 5.39 (H-19), 4.08 (H-
12b), 3.37 (H-12a), 2.88 (H-15b), 1.87 (H-15a), 2.55 (H-20b), 2.55 (H-20a), 2.01 (H-16b), 1.86 
(H-16a), 1.54 (H-25), 1.46 (H-26), 1.28 (H-23), 1.19 (H-24); ESIMS m/z 703.35 [M+H]+. 
(S)-MTPA Ester of 5.4: 1H NMR (500 MHz, pyridine-d5) δ 5.53 (H-21), 5.45 (H-19), 4.11 (H-
12b), 3.38 (H-12a), 2.85 (H-15b), 1.84 (H-15a), 2.69 (H-20b), 2.58 (H-20a), 1.99 (H-16b), 1.84 
(H-16a), 1.54 (H-25), 1.47 (H-26), 1.16 (H-23), 1.10 (H-24); ESIMS m/z 703.35 [M+H]+. 
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(R)-MTPA Ester of 5.5: 1H NMR (500 MHz, pyridine-d5) δ 6.03 (H-21), 3.09 (H-12b), 2.92 (H-
12a), 2.83 (H-15b), 1.96 (H-15a), 2.75 (H-19b), 1.42 (H-19a), 2.18 (H-20b), 2.08 (H-20a), 1.90 
(H-16b), 1.86 (H-16a), 1.50 (H-25), 1.23 (H-23), 1.21 (H-26), 1.11 (H-24). 
(S)-MTPA Ester of 5.5: 1H NMR (500 MHz, pyridine-d5) δ 6.02 (H-21), 3.07 (H-12b), 2.90 (H-
12a), 2.84 (H-15b), 1.97 (H-15a), 2.74 (H-19b), 1.39 (H-19a), 2.14 (H-20b), 1.86 (H-20a), 1.90 
(H-16b), 1.86 (H-16a), 1.50 (H-25), 1.33 (H-23), 1.19 (H-26), 1.14 (H-24). 
(R)-MTPA Ester of 5.12: 1H NMR (500 MHz, pyridine-d5) δ 5.96 (H-21), 4.35 (H-12b), 3.24 
(H-12a), 3.48 (H-20b), 3.07 (H-20a), 2.81 (H-15b), 1.87 (H-15a), 1.96 (H-16b), 1.94 (H-16a), 
1.50 (H-25), 1.45 (H-26), 1.34 (H-23), 1.31 (H-24). 
(S)-MTPA Ester of 5.12: 1H NMR (500 MHz, pyridine-d5) δ 5.96 (H-21), 4.35 (H-12b), 3.24 
(H-12a), 3.59 (H-20b), 3.13 (H-20a), 2.80 (H-15b), 1.85 (H-15a), 1.94 (H-16b), 1.92 (H-16a), 
1.49 (H-25), 1.45 (H-26), 1.24 (H-23), 1.19 (H-24). 
 
5.4.5 ECD Calculations of 5.13 
Conformational analyses were performed using Spartan'10.212 Geometry, frequency and 
ECD calculations were carried out at the DFT level with Gaussian 09.213 SpecDis 1.60 was used 
to average single ECD spectra after Boltzmann statistical weighting.214 
 
5.4.6 Zebrafish maintenance 
Wild-type (WT) AB/TU Danio rerio (zebrafish) were maintained as previously 
described.215 Fertilized embryos were collected following natural spawning in 1× E3 medium 
(286 mg/L NaCl, 13 mg/L KCl, 48 mg/L CaCl2·2H2O, 40 mg/L MgSO4, 0.01% methylene blue) 
and allowed to develop at 28.5 °C. 
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5.4.7 Zebrafish phenotype screen 
Crude fungal extracts were assayed based on our previously reported zebrafish phenotype 
screen197. Crude and semi-pure extracts were prepared in dimethyl sulfoxide (DMSO) as 2 
mg/ml stocks.  Pure fungal compounds were prepared as 10 mM stocks. Azinphos-methyl 
(APM), tetraisopropyl pyrophosphoramide (iso-OMPA) and physostigmine were prepared as 100 
mM stocks in DMSO. Further dilutions were carried out in DMSO. 
 
5.4.8 In situ hybridization 
In situ hybridizations were performed as previously described using digoxigenin-labeled 
riboprobes for xirp2a (xin actin binding repeat containing 2a)216. Embryos were cleared in 2:1 
benzyl benzoate/benzyl alcohol solution and documented using an Olympus SZX12/DP71 
imaging system (Olympus Corporation, Japan). RNA Reference Sequence deposited in ZFIN 
(zfin.org) was used in designing the riboprobe. 
 
5.4.9 Acetylcholinesterase and butyrylcholinesterase inhibition assays 
AChE inhibition was determined using QuantiChromTM Acetylcholinesterase Inhibitor 
Screening Kit following manufacturer’s protocol (BioAssay Systems – Hayward, CA). Briefly, 
test compounds were incubated with AChE from E. electricus (Sigma-Aldrich) for 15 min. 
Absorbance was measured at T= 0 min and T= 15 min after addition of assay buffer containing 
AChE substrate and 5,5’-dithiobis (2-nitrobenzoic acid) (DTNB). The same kit and protocol 
were used to measure butyrylcholinesterase inhibition by substituting butyrylcholinesterase from 
equine serum and s-butyrylthiocholine iodide as substrate. Both reagents were purchased from 
Sigma-Aldrich. Raw absorbance readings were corrected against ‘No Enzyme’ control and 
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normalized to ‘No Inhibitor’ control. Data was plotted and analyzed using Graph Pad Prism 
v7.02. 
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Figure A1. 1H NMR spectrum of compound 3.1 (CDCl3, 400 MHz) 
	  
	  
Figure A2. 13C NMR spectrum of compound 3.1 (CDCl3, 100 MHz)  
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Figure A3. COSY spectrum of compound 3.1 (CDCl3, 400 MHz) 
	  
	  
Figure A4. HSQC spectrum of compound 3.1 (CDCl3, 400 MHz)  
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Figure A5. HMBC Spectrum of Compound 3.1 (CDCl3, 400 MHz) 
 
 
Figure A6. 1H NMR Spectrum of Compound 3.3 (MeOH-d4, 400 MHz) 
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Figure A7. 13C NMR Spectrum of Compound 3.3 (MeOH-d4, 100 MHz) 
 
	  
Figure A8. COSY Spectrum of Compound 3.3 (MeOH-d4, 400 MHz)  
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Figure A9. HSQC Spectrum of Compound 3.3 (MeOH-d4, 400 MHz) 
 
 
Figure A10. HMBC Spectrum of Compound 3.3 (MeOH-d4, 400 MHz)  
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Figure A11. HRESIMS Spectrum of Compound 3.3 
 
	  
Figure A12. 1H NMR Spectrum of Compound 3.4 (MeOH-d4, 400 MHz)  
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Figure A13. 13C NMR Spectrum of Compound 3.4 (MeOH-d4, 100 MHz) 
 
	  
Figure A14. COSY Spectrum of Compound 3.4 (MeOH-d4, 400 MHz)  
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Figure A15. HSQC Spectrum of Compound 3.4 (MeOH-d4, 400 MHz) 
 
 
Figure A16. HMBC spectrum of compound 3.4 (MeOH-d4, 400 MHz)  
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Figure A17. HRESIMS spectrum of compound 3.4. 
 
 
Figure A18. 1H NMR spectrum of compound 3.5 (MeOH-d4, 400 MHz)  
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Figure A19. 13C NMR spectrum of compound 3.5 (MeOH-d4, 100 MHz) 
 
	  
Figure A20. COSY spectrum of compound 3.5 (MeOH-d4, 400 MHz)  
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Figure A21. HSQC spectrum of compound 3.5 (MeOH-d4, 400 MHz) 
 
 
Figure A22. HMBC spectrum of compound 3.5 (MeOH-d4, 400 MHz)  
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Figure A23. HRESIMS spectrum of compound 3.5 
 
 
Figure A24. 1H NMR spectrum of compound 3.6 (MeOH-d4, 400 MHz)  
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Figure A25. 13C NMR spectrum of compound 3.6 (MeOH-d4, 100 MHz) 
 
	  
Figure A26. COSY spectrum of compound 3.6 (MeOH-d4, 400 MHz)  
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Figure A27. HSQC spectrum of compound 3.6 (MeOH-d4, 400 MHz) 
 
 
Figure A28. HMBC spectrum of compound 3.6 (MeOH-d4, 400 MHz)  
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Figure A29. HRESIMS spectrum of compound 3.6 
 
 
Figure A30. 1H NMR spectrum of compound 3.7 (MeOH-d4, 400 MHz)  
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Figure A31. 13C NMR spectrum of compound 3.7 (MeOH-d4, 100 MHz) 
 
	  
Figure A32. COSY spectrum of compound 3.7 (MeOH-d4, 400 MHz)  
OH
H3CO OCH3
OCH3
O
O
OH
H3CO OCH3
OCH3
O
O
	   135	  
	  
Figure A33. HSQC spectrum of compound 3.7 (MeOH-d4, 400 MHz) 
 
 
Figure A34. HMBC spectrum of compound 3.7 (MeOH-d4, 400 MHz)  
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Figure A35. HRESIMS spectrum of compound 3.7 
 
 
Figure A36. 1H NMR spectrum of compound 3.8 (MeOH-d4, 400 MHz)  
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Figure A37. 13C NMR spectrum of compound 3.8 (MeOH-d4, 100 MHz) 
 
	  
Figure A38. COSY spectrum of compound 3.8 (MeOH-d4, 400 MHz)  
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Figure A39. HSQC spectrum of compound 3.8 (MeOH-d4, 400 MHz) 
 
 
Figure A40. HMBC spectrum of compound 3.8 (MeOH-d4, 400 MHz)  
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Figure A41.ROESY spectrum of compound 3.8 (MeOH-d4, 400 MHz) 
 
 
Figure A42. HRESIMS spectrum of compound 3.8  
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Figure A43. 1H NMR spectrum of compound 3.9 (MeOH-d4, 400 MHz) 
 
 
Figure A44. 13C NMR spectrum of compound 3.9 (MeOH-d4, 100 MHz)  
O
HO
H3CO
OH O
O
OH
O
HO
H3CO
OH O
O
OH
	   141	  
	  
Figure A45. COSY spectrum of compound 3.9 (MeOH-d4, 400 MHz) 
 
	  
Figure A46. HSQC spectrum of compound 3.9 (MeOH-d4, 400 MHz)  
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Figure A47. HMBC spectrum of compound 3.9 (MeOH-d4, 400 MHz) 
 
 
Figure A48.ROESY spectrum of compound 3.9 (MeOH-d4, 400 MHz)  
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Figure A49. HRESIMS spectrum of compound 3.9 
 
 
Figure A50. 1H NMR spectrum of compound 3.10 (MeOH-d4, 400 MHz)  
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Figure A51. 13C NMR spectrum of compound 3.10 (MeOH-d4, 100 MHz) 
 
	  
Figure A52. COSY spectrum of compound 3.10 (MeOH-d4, 400 MHz)  
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Figure A53. HSQC spectrum of compound 3.10 (MeOH-d4, 400 MHz) 
 
 
Figure A54. HMBC spectrum of compound 3.10(MeOH-d4, 400 MHz)  
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Figure A55.ROESY spectrum of compound 3.10 (MeOH-d4, 400 MHz) 
 
 
Figure A56. HRESIMS spectrum of compound 3.10  
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Figure A57. 1H NMR spectrum of compound 3.11 (MeOH-d4, 400 MHz) 
 
 
Figure A58. 13C NMR spectrum of compound 3.11 (MeOH-d4, 100 MHz)  
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Figure A59. COSY spectrum of compound 3.11 (MeOH-d4, 400 MHz) 
 
	  
Figure A60. HSQC spectrum of compound 3.11 (MeOH-d4, 400 MHz)  
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Figure A61. HMBC spectrum of compound 3.11 (MeOH-d4, 400 MHz) 
 
 
Figure A62.ROESY spectrum of compound 3.11 (MeOH-d4, 400 MHz)  
O
HO
H3CO
OH O
O OH
O
HO
H3CO
OH O
O OH
	   150	  
 
Figure A63. HRESIMS spectrum of compound 3.11 
 
 
Figure A64. 1H NMR spectrum of compound 3.12 (MeOH-d4, 400 MHz)  
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Figure A65. 13C NMR spectrum of compound 3.12 (MeOH-d4, 100 MHz) 
 
	  
Figure A66. COSY spectrum of compound 3.12 (MeOH-d4, 400 MHz)  
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Figure A67. HSQC spectrum of compound 3.12 (MeOH-d4, 400 MHz) 
 
 
Figure A68. HMBC spectrum of compound 3.12 (MeOH-d4, 400 MHz)  
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Figure A69.ROESY spectrum of compound 3.12 (MeOH-d4, 400 MHz) 
 
 
Figure A70. HRESIMS spectrum of compound 3.12  
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Figure A71. 1H NMR spectrum of compound 3.13 (MeOH-d4, 400 MHz) 
 
 
Figure A72. 13C NMR spectrum of compound 3.13 (MeOH-d4, 100 MHz)  
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Figure A73. COSY spectrum of compound 3.13 (MeOH-d4, 400 MHz) 
 
	  
Figure A74. HSQC spectrum of compound 3.13 (MeOH-d4, 400 MHz)  
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Figure A75. HMBC spectrum of compound 3.13 (MeOH-d4, 400 MHz) 
 
 
Figure A76.ROESY spectrum of compound 3.13 (MeOH-d4, 400 MHz)  
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Figure A77. HRESIMS spectrum of compound 3.13 
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Figure B.1. LC-MS analysis (selected ion at m/z 356.15 under ESI¯ mode) for FDAA 
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Figure B.4. 1H NMR Spectrum of Compound 4.4 (DMSO-d6, 500MHz) 
 
	  
Figure B.5. 13C NMR Spectrum of Compound 4.4 (DMSO-d6, 100MHz) 
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Figure B.6. 1H NMR Spectrum of Compound 4.5 (DMSO-d6, 500MHz) 
 
 
Figure B.7. 13C NMR Spectrum of Compound 4.5 (DMSO-d6, 100MHz) 
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Figure B.8. COSY Spectrum of Compound 4.5 (DMSO-d6) 
 
 
Figure B.9. HSQC Spectrum of Compound 4.5 (DMSO-d6)  
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Figure B.10. HMBC Spectrum of Compound 4.5 (DMSO-d6) 
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Figure B.12. 1H NMR Spectrum of Compound 4.6 (DMSO-d6, 500MHz) 
 
Figure B.13. 13C NMR Spectrum of Compound 4.6 (DMSO-d6, 100MHz) 
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Figure B.14. 1H NMR Spectrum of Compound 4.7 (DMSO-d6, 500MHz) 
 
 
Figure B.15. 13C NMR Spectrum of Compound 4.7 (DMSO-d6, 100MHz) 
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Figure B.16. COSY Spectrum of Compound 4.7 (DMSO-d6) 
 
 
Figure B.17. HSQC Spectrum of Compound 4.7 (DMSO-d6)  
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Figure B.18. HMBC Spectrum of Compound 4.7 (DMSO-d6) 
 
 
Figure B.19. ROESY Spectrum of Compound 4.7 (DMSO-d6)  
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Figure B.20. CD Spectra of Compounds 4.1-4.3. 
 
 
Figure B.21. CD Spectra of Compounds 4.4, 4.6. 
 
Figure B.22. CD Spectra of Compounds 4.7-4.8.   
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Table C1. Identification codes and associated information for the fungal isolate 
Fungus name used in this 
report: Penicillium sp. 
Full ID code for the sample 
from which the fungal isolated 
was obtained: 
10263, soil  
SHAREOK link for citizen-
science-derived sample (if 
available):  
https://shareok.org/handle/11244/300790 
Internal lab sample ID code: OK0263 
Full fungal isolate ID code: OK0263 PDA-20 
Plate number and well for 
fungal initial extract: 
87-B1 
 
First chemistry notebook code 
assigned to fungal extract and 
PDA chromatogram of the 
crude extract: 
 
 
LCMS condition: MeCN-H2O gradient containing 0.1% 
HCOOH (10:90-100:0 in 15 min) 
Pictures of fungal isolate: 
 
ITS sequence used to assign 
taxonomy: 
 
GCGGGTGACAAAGCCCCATACGCTCGAGGACCGGAC
GCGGTGCCGCCGCTGCCTTTCGGGCCCGTCCCCCGGA
AATCGGAGGACGGGGCCCAACACACAAGCCGGGCTT
GAGGGCAGCAATGACGCTCGGACAGGCATGCCCCCC
GGAATACCAGGGGGCGCAATGTGCGTTCAAAGACTC
GATGATTCACTGAATTTGCAATTCACATTACGTATCG
CATTTCGCTGCGTTCTTCATCGATGCCGGAACCAAGA
GATCCGTTGTTGAAAGTTTTAAATAATTTATATTTTC
ACTCAGACTTCAATCTTCAGACAGAGTTCGAGGGTGT
CTTCGGCGGGCGCGGGCCCGGGGGCGTGAGCCCCCC
GGCGGCCAGTTAAGGCGGGCCCGCCGAAGCAACAAG
GTAAAATAAACACGGGTGCGGAGGTTGGACCCAGAG
GGCCCTCACTCGGTAATGATCCTTCCGCAGGTTCACC
TACGGAAACCTTGTTACGACTTTTACTTCC 
GenBank accession number: MK722362 
Notes on the taxonomic 
affiliation of the fungal isolate: 
Multiple Penicillium species all at 98.90% identity, 100% 
query cover, cannot assign species level identification, 
BLAST date April 1 2019 
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Table C2. Dose curve analysis of toxic crude fungal extracts. 
Sample ID Phenotype Observeda Dose, 
µg/mLb 
P86-B12 Edema 0.1 
P86-C4 Misshapen tail 1 
P86-C6 Misshapen tail, necrosis 2 
P86-D7 Misshapen tail, necrosis 1 
P86-D10 Edema, necrosis, enlarged hindbrain 0.2 
P86-E9 Hemorrhage 0.2 
P86-F1 Edema, misshapen tail, necrosis, lack of blood circulation 0.1 
P87-A3 Edema 1 
P87-A5 Misshapen tail 2 
P87-A7 Growth arrest, necrosis 1 
P87-A8 N - 
P87-A9 Necrosis 0.1 
P87-A11 N - 
P87-A12 N - 
P87-B2 N - 
P87-B5 N - 
P87-B8 Misshapen tail and body 1 
P87-B10 N - 
P87-B12 N - 
P87-C2 N - 
P87-C8 N - 
P87-C9 Hemorrhage 0.1 
P87-C10 N - 
P87-D8 N - 
P87-E8 N - 
P87-F12 N - 
P87-H6 Hemorrhage 2 
P87-H8 N - 
GL6-A8 N - 
GL6-B8 N - 
GL6-B12 N - 
GL6-F9 Small embryo 10 
GL6-F10 Loss of pigmentation, impaired motility 2 
GL7-H8 N - 
 aN- no phenotype observed at all concentrations tested. 
 bDose when phenotype was initially observed. 
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Table C3. ROESY correlations of compounds 5.4. 
Proton ROESY correlations 
H-12 (δH 2.71) H-25 (δH 1.44), H-26 (δH 1.19) 
H-12 (δH 3.14) OH-13 (δH 6.72), H-19 (δH 4.91) 
OH-13 (δH 6.72) H-12 (δH 3.14), H-15 (δH 2.38), H-19 (δH 4.91), H-23 (δH 1.10) 
H-15 (δH 2.38) OH-13 (δH 6.72), OH-17 (δH 6.81) 
H-16 (δH 1.73) H-23 (δH 1.10) 
H-16 (δH 1.94) H-24 (δH 1.04), H-25 (δH 1.44), H-26 (δH 1.19) 
OH-17 (δH 6.81) H-15 (δH 2.38), H-19 (δH 4.91), H-23 (δH 1.10) 
H-19 (δH 4.91) H-12 (δH 3.14), OH-13 (δH 6.72), OH-17 (δH 6.81),  
OH-21(δH 5.44) 
OH-19 (δH 3.63) H-12 (δH 3.14), H-26 (δH 1.19) 
H-20 (δH 2.16) H-24 (δH 1.04), H-26 (δH 1.19), OH-19 (δH 3.63) 
H-20 (δH 2.05) OH-19 (δH 3.63) 
H-21 (δH 3.66) H-23 (δH 1.10), H-24 (δH 1.04),H-20 (δH 2.05, δH 2.16) 
OH-21 (δH 5.44) H-23 (δH 1.10), H-19 (δH 4.91) 
 
Table C4. ROESY correlations of compounds 5.5. 
Proton ROESY correlations 
H-12 (δH 2.19) H-19 (δH 1.14), OH-13 (δH 6.66) 
H-12 (δH 2.60) H-25 (δH 1.34), H-26 (δH 1.07) 
OH-13 (δH 6.66) H-12 (δH 2.19), H-15 (δH 2.28), H-19 (δH 2.11), H-23 (δH 0.91) 
H-15 (δH 1.57) H-25 (δH 1.37) 
H-15 (δH 2.28) OH-13 (δH 6.66), OH-17 (δH 6.08) 
H-16 (δH 1.61) H-23 (δH 0.91) 
H-16 (δH 1.89) H-24 (δH 0.84), H-25 (δH 1.34), H-26 (δH 1.07) 
OH-17 (δH 6.08) H-15 (δH 2.28), H-16 (δH 1.61), H-19 (δH 2.11), H-23 (δH 0.91) 
H-19 (δH 1.14) H-26 (δH 1.07) 
H-19 (δH 2.11) H-21 (δH 3.72), OH-17 (δH 6.08) 
H-21 (δH 3.72) H-19 (δH 2.11), H-23 (δH 0.91) 
OH-21 (δH 4.19) H-23 (δH 0.91) 
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Table C5. ROESY correlations of compounds 5.8. 
Proton ROESY correlations 
H-12 (δH 2.65) H-25 (δH 1.38), H-26 (δH 1.10)  
H-12 (δH 2.95) H-19 (δH 4.74) 
OH-13 (δH 6.63) H-19 (δH 4.74) 
H-15 (δH 1.63) H-24 (0.96), H-25 (δH 1.38) 
H-15 (δH 2.23) OH-17 (δH 6.46) 
H-16 (δH 1.63) H-23 (δH 1.10) 
H-16 (δH 1.96) H-25 (δH 1.38), H-26 (δH 1.10) 
OH-17 (δH 6.46) H-15 (δH 2.23), H-19 (δH 4.74) 
H-19 (δH 4.74) H-23 (δH 1.10), H-12 (δH 2.95), OH-13 (δH 6.63), OH-17 (δH 6.46)  
OH-19 (δH 5.05) H-26 (δH 1.10) 
H-20 (δH 2.54) H-23 (δH 1.10) 
H-20 (δH 2.74) H-24 (δH 0.91) 
 
Table C6. ROESY correlations of compounds 5.12. 
Proton ROESY correlations 
H-12 (δH 2.72) H-25 (δH 1.37), H-26 (δH 1.24)  
H-12 (δH 3.39) OH-13 (δH 6.44) 
OH-13 (δH 6.44) H-12 (δH 3.39), H-15 (δH 2.22) 
H-15 (δH 1.60) H-25 (δH 1.37) 
H-15 (δH 2.22) OH-13 (δH 6.44), OH-17 (δH 6.73) 
H-16 (δH 1.74) H-23 (δH 0.94), H-24 (δH 1.11), OH-17 (δH 6.73)  
H-16 (δH 1.92) H-24 (δH 1.11), H-25 (δH 1.37), H-26 (δH 1.24) 
OH-17 (δH 6.73) H-15 (δH 2.22), H-16 (δH 1.74), H-23 (δH 0.94)  
H-20 (δH 2.65) H-21 (δH 3.94), H-24 (δH 1.11), H-26 (δH 1.24) 
H-20 (δH 2.79) H-23 (δH 0.94), 
H-21 (δH 3.94) H-23 (δH 0.94), H-24 (δH 1.11), H-26 (δH 1.24) 
OH-21 (δH 5.10) H-23 (δH 0.94) 
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Table C7. ROESY correlations of compounds 5.13. 
Proton ROESY correlations 
H-12 (δH 2.31) H-25 (δH 1.30), H-26 (δH 1.10)  
H-12 (δH 2.67) H-13 (δH 1.78) 
H-13 (δH 1.78) H-12 (δH 2.67) 
H-15 (δH 2.11) H-25 (δH 1.30) 
H-16 (δH 1.62) H-24 (δH 1.02), H-25 (δH 1.30), H-26 (δH 1.10) 
H-16 (δH 1.74) H-23 (δH 1.09) 
  H-17 (δH 1.86) H-23 (δH 1.09) 
 
 
Figure C1. Zebrafish phenotype screen reveals fungal extracts that impaired motility. Frame-by-
frame images representing response of zebrafish embryos to external stimulus (represented by 
black line).  
DMSO
APM
10 µM
crude extract
8.35 µg/ml
subfraction 2
10 µg/mL
subfraction 1
10 µg/mL
subfraction 4
10 µg/mL
subfraction 3
10 µg/mL
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Figure C2. 1H-NMR spectrum of compound 5.4 in Acetone-d6 (500 MHz). 
 
 
Figure C3. 13C-NMR spectrum of compound 5.4 in Acetone-d6 (100 MHz). 
O
O
OH
HO
OH
O
O
OH
O
O
OH
HO
OH
O
O
OH
	   181	  
 
Figure C4. 1H-1H COSY spectrum of compound 5.4 in Acetone-d6 (500 MHz). 
 
 
Figure C5. HSQC spectrum of compound 5.4 in Acetone-d6 (500 MHz). 
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Figure C6. HMBC spectrum of compound 5.4 in Acetone-d6 (500 MHz). 
 
 
Figure C7. ROESY spectrum of compound 5.4 in Acetone-d6 (500 MHz). 
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Figure C8. HRESIMS of compound 5.4.   
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Figure C9. 1H-NMR spectrum of compound 5.5 in CDCl3 (500 MHz). 
 
 
Figure C10. 13C-NMR spectrum of compound 5.5 in CDCl3 (100 MHz). 
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Figure C11. 1H-1H COSY spectrum of compound 5.5 in CDCl3 (500 MHz). 
 
 
Figure C12. HSQC spectrum of compound 5.5 in CDCl3 (500 MHz). 
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Figure C13. HMBC spectrum of compound 5.5 in CDCl3 (500 MHz). 
 
 
Figure C14. 1H-NMR spectrum of compound 5.5 in DMSO-d6 (600 MHz). 
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Figure C15. 1H-1H COSY spectrum of compound 5.5 in DMSO-d6 (600 MHz). 
 
Figure C16. HSQC spectrum of compound 5.5 in DMSO-d6 (600 MHz). 
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Figure C17. HMBC spectrum of compound 5.5 in DMSO-d6 (600 MHz). 
 
Figure C18. ROESY spectrum of compound 5.5 in DMSO-d6 (500 MHz). 
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Figure C19. HRESIMS of compound 5.5.   
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Figure C20. 1H-NMR spectrum of compound 5.8 in DMSO-d6 (500 MHz). 
 
 
Figure C21. 13C-NMR spectrum of compound 5.8 in DMSO-d6 (100 MHz). 
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Figure C22. 1H- 1H spectrum of compound 5.8 in DMSO-d6 (500 MHz). 
 
 
Figure C23. HSQC spectrum of compound 5.8 in DMSO-d6 (500 MHz). 
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Figure C24. HMBC spectrum of compound 5.8 in DMSO-d6 (500 MHz). 
 
 
Figure C25. ROESY spectrum of compound 5.8 in DMSO-d6 (500 MHz). 
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Figure C26. HRESIMS of compound 5.8.  
[M+Na]+
[M+H]+
O
O
OH
OH
O
O
O
OH
	   194	  
 
Figure C27. 1H-NMR spectrum of compound 5.12 in DMSO-d6 (500 MHz). 
 
 
Figure C28. 13C-NMR spectrum of compound 5.12 in DMSO-d6 (100 MHz). 
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Figure C29. 1H-1H spectrum of compound 5.12 in DMSO-d6 (500 MHz). 
 
 
Figure C30. HSQC spectrum of compound 5.12 in DMSO-d6 (500 MHz). 
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Figure C31. HMBC spectrum of compound 5.12 in DMSO-d6 (500 MHz). 
 
 
Figure C32. ROESY spectrum of compound 5.12 in DMSO-d6 (500 MHz). 
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Figure C33. HRESIMS of compound 5.12.  
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Figure C34. 1H-NMR spectrum of compound 5.13 in DMSO-d6 (500 MHz). 
 
 
Figure C35. 13C-NMR spectrum of compound 5.13 in DMSO-d6 (100 MHz). 
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Figure C36. 1H-1H spectrum of compound 5.13 in DMSO-d6 (500 MHz). 
 
 
Figure S37. HSQC spectrum of compound 5.13 in DMSO-d6 (500 MHz). 
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Figure C38. HMBC spectrum of compound 5.13 in DMSO-d6 (500 MHz). 
 
 
Figure C39. ROESY spectrum of compound 5.13 in DMSO-d6 (500 MHz). 
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Figure C40. HRESIMS of compound 5.13.  
[M+Na]+
[M+H]+
O
OO
O
O H
H
	   202	  
 
Figure C41. 1H-NMR spectrum of compound 5.14 in Acetone-d6 (500 MHz). 
 
 
Figure C42. 13C-NMR spectrum of compound 5.14 in Acetone-d6 (100 MHz). 
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Figure C43. 1H-1H spectrum of compound 5.14 in Acetone-d6 (500 MHz). 
 
 
Figure C44. HSQC spectrum of compound 5.14 in Acetone-d6 (500 MHz). 
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Figure C45. HMBC spectrum of compound 5.14 in Acetone-d6 (500 MHz). 
 
 
Figure C46. ROESY spectrum of compound 5.14 in Acetone-d6 (500 MHz). 
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Figure C47. HRESIMS of compound 5.14.  
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Abbreviations 
 
ITS               internal transcribed spacer 
RPB1           largest subunit of RNA polymerase 
RPB2           second largest subunit of RNA polymerase 
tub2/BenA    β-tubulin 
tef1               translation elongation factor 1- α 
MCM7         mini-chromosome maintenance protein 
CaM             partial calmodulin 
BLAST        basic local alignment search tool 
CZI              Czapek Ivermectin Agar 
 PCR            polymerase chain reaction 
SI                 selectivity index 
VLC            vacuum liquid chromatography 
MTPA         α-methoxy-α-trifluoromethylphenylacetyl 
FDAA         1-Fluoro-2-4-Dinitrophenyl-5- L-Alanine Amide 
ATCC         the American Type Culture Collection 
ACh            acetylcholine 
AChE         acetylcholinesterase 
BuChE        butyrycholinesterase 
CNS            central nervous system 
AZM           azinphos-methyl 
iso-OMPA  tetraisopropyl-pyrophosphoramide     
xirp2a         xin actin binding repeat containing 2a 
